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ABSTRACT 
The endometrium is a unique tissue in the adult human body because it is the only site where 
physiological renewal of vessels, angiogenesis, occurs. The regulation of this process under 
normal conditions is not fully understood. Heavy Menstrual Bleeding of endometrial origin 
(HMB-E) and Endometrial Cancer (EC) are two diseases which can neither occur nor be 
sustained without the process of angiogenesis. Clinically, both diseases are also associated 
with a strong hereditary component where female relatives of affected patients demonstrate a 
high incidence of the same condition. The aim of this thesis is to further elucidate the 
angiogenic and hereditary components of these diseases. The first part of this project (studies 
I and II) explores HMB-E and its relationship to angiogenesis, while the second part (studies 
III and IV) examines the association between incidence of EC in relation to previously known 
and unknown hereditary factors.  
Study I explored the relationship between expression of the pro-angiogenic factor SDF-1 and 
the number of circulating epithelial progenitor cells (EPCs) in peripheral blood in 10 women 
with a confirmed diagnosis of HMB-E, and compared these results with those of 10 healthy 
controls using flow cytometry and cell culture.  The results showed a significant decrease of 
SDF-1 throughout the entire menstrual cycle, a 16% decrease overall, with the most 
substantial decline noted during the proliferative phase of the menstrual cycle in women with 
HMB-E, compared with controls. The number of EPCs in peripheral blood was also 
significantly reduced in HMB-E patients, showing a significant positive correlation between 
number of EPCs and SDF-1 levels. These findings are consistent with the literature, which 
has shown that SDF-1 is essential for recruitment of EPCs from bone marrow into the 
bloodstream, and further suggests that this signaling axis is important for physiological 
angiogenesis in the endometrium.        
Study II addressed microvascular morphology within the endometrium among 17 women 
with HMB-E and compared the results with 10 controls, using immunohistochemistry and 
electron microscopy. We found a significant decrease in pericyte coverage of microvessels 
during the mid-proliferative phase, as well as an increase in vessel perimeter among women 
with HMB-E. We also found a negative correlation between vascular expression of the 
known pro-angiogenic factor VEGF-A and pericyte coverage. These findings indicate that 
HMB-E may be caused by altered microvessel maturation and that the overexpression of 
VEGF-A seen in HMB-E might be the underlying cause. 
Study III examined the clinical challenge of reducing EC risk in women with Lynch 
Syndrome (LS), who collectively have a 42-54% lifetime risk of developing this disease. 
Sweden has no national guidelines regarding surveillance of these women for gynecological 
cancers. Therefore, we took a retrospective look at the modalities and screening intervals that 
are currently used in Sweden for known LS carriers. In all, 86 women had a known LS 
mutation and participated in various screening programs.  
 
Of the 41 women who decided to have prophylactic hysterectomy while under screening, 
EC/complex hyperplasia was found in the uterus of 4 of them postoperatively. The remaining 
45 women opted for annual surveillance without prophylactic surgery. In this group, 9 
women developed EC, 2 complex endometrial hyperplasia and 2 ovarian cancers, both of 
which were found at an early stage by ultrasound. Among these 9 EC cases, 5 were detected 
through endometrial biopsy during regular surveillance at an asymptomatic stage, as were the 
two hyperplasias. Ultrasonography failed to detect any of these cases. The remaining 4 EC 
cases were associated with occult bleeding between screening visits. No difference in tumor 
stage was noted between the ECs found because they were symptomatic and those found 
through routine surveillance. No mortality resulted from the gynecological cancers found in 
the study group as a whole. The results did not reveal any clear benefit from conducting 
annual gynecological screening for women with LS if the endpoint is to reduce mortality. The 
single most important factor may be knowledge and awareness among doctors and patients of 
LS and the associated increased risk of cancer, which should trigger prompt investigation if 
symptoms develop. However, when screening is undertaken, endometrial biopsy seems to be 
the diagnostic modality of choice to detect asymptomatic ECs or hyperplasia.      
Study IV investigated additional genetic risk factors that help to explain the twofold increase 
in relative risk of developing EC among women with a first or second degree relative who 
have the disease, even when known single gene mutations are excluded. After genotype 
studies and quality control, a total of 332,906 SNPs among genotypes derived from 1116 EC 
cases and 5021 controls were compared. The results showed five haplotypes located on 
chromosomes no. 2, 10, 13, 15 and 20 that were significantly more common among EC 
patients than controls. The frequency of these haplotypes in the EC population ranged 
between 1.58-3.69% and the odds ratio for EC ranged between 1.58-3.05 for the five 
haplotypes. The five haplotypes were found in regions of the genome with no previously 
known link to EC development and without close proximity to any genes known to be 
involved with this disease. These findings add to our knowledge about the genetic risk factors 
associated with EC and may offer one explanation for why the incidence and clinical course 
of this disease differs among people of different ethnic backgrounds. Nevertheless, other risk 
factors must be taken into account when interpreting these results, including known 
environmental risk factors for EC and those that could potentially be inherited, such as 
obesity.  
In conclusion, this thesis provides new information concerning the angiogenic and hereditary 
factors involved in development of both HMB-E and EC. The papers add to our knowledge 
about how the SDF-1 axis is involved in endometrial vascular regeneration during 
physiological endometrial angiogenesis and how vascular maturation appears to be 
inadequate in HMB-E. The thesis also confirms the knowledge about the role of known 
inherited cancer syndromes in development of EC, and finds that gynecological surveillance 
per se does not seem to reduce mortality from gynecological cancer; instead, the most 
important protective factor appears to be knowledge and awareness of the cancer syndrome 
among both carriers of the syndrome and the care providers. 
  
Additionally, this thesis found five haploptypes that are overrepresented in a Swedish cohort 
of EC cases, which may explain some of the risk of inheriting EC. The future challenge will 
be to examine the potential link between HMB-E and EC from the perspective of both 
clinical and basic research.      
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1 INTRODUCTION 
1.1 Angiogenetic and Hereditary physiology 
1.1.1 Endometrial anatomy and physiology 
The human uterine wall consists of two anatomically distinct layers. The innermost layer, 
known as the myometrium, consists of smooth muscle and is thicker than the superficial 
layer, known as the endometrium, which surrounds the uterine cavity. The endometrium can 
then be further subdivided into the basal and functional layers. The basal layer, adjacent to 
the myometrium, does not shed during menstruation, which distinguishes it from the adjacent 
functional layer that develops in conjunction with the menstrual cycle and sheds during 
menstruation. The functional layer consists of a single-cell layer of columnar epithelium 
adjacent to the uterine cavity, with underlying vascular dense glandular stroma. 
Picture 1: Human endometrial anatomy. (Williams Obstetrics 24e, McGraw-Hill Medical 2014©) 
The sex steroid hormones produced in the ovaries, mainly estrogen and progesterone, control 
growth and shedding of the functional layer in the endometrium during the menstrual cycle. 
Shedding usually occurs over a period of 4-5 days. Estrogen levels then increase to a point 
where they begin to stimulate the cells in the basal layer to regenerate a new functional layer. 
This is referred to as the proliferative phase of the menstrual cycle (1).  
When ovulation later occurs around day 14 in the cycle, hormonal production in the ovaries 
shifts toward progesterone produced by the corpus luteum. This process halts mitotic activity 
in the endometrial cells, while causing maturation of vessels and early decidualization 
changes in the stroma. This process describes the secretory phase of the menstrual cycle.  
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If embryo implantation fails to occur during the remaining days of the cycle, the corpus 
luteum will eventually start to deteriorate, thereby causing progesterone levels to drop, which 
in turn leads to the breakdown and shedding of the functional endometrial layer. Exactly how 
progesterone withdrawal leads to this event on a cellular level is not completely understood 
(2), but we do know that such withdrawal leads to vasoconstriction of the spiral arterioles, 
causing hypoxia, which in turn triggers an inflammatory response and shedding of the 
necrotic material. The necrotic tissue sheds over a period of 1-2 days, after which endometrial 
healing begins over the remaining days of the bleeding period, a process where inflammatory, 
coagulatory, angiogenic and cellular factors all play crucial roles for tissue stabilization, 
culminating in hemostasis and healing (1). 
Picture 2: Human menstrual physiology (Slideshare_Physiology of Menstruation, Dr Anusha Rao©)  
Observations within the uterine cavity during menstrual bleeding have shown that 
endometrial shedding is not an orderly process. Instead, patchy loss of the old layer occurs 
with islands of bleeding and shedding, while tissue regeneration simultaneously occurs in 
other areas of the uterine cavity, which implies that the process is under local control and 
involves a delicate balance of various molecular factors within the endometrium (2).  
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Molecular regulation of endometrial shedding, repair and regeneration is believed to entail a 
multistep process. The process begins with the previously described withdrawal of 
progesterone at the end of the menstrual cycle. As progesterone levels drop, the functional 
layer is already in a proinflammatory state, which is necessary for embryonic implantation to 
occur (3). Progesterone withdrawal leads to five observable changes: an increase in local 
expression of the prostaglandin synthesizing enzymes COX 1 and 2 (i); a subsequent increase 
in prostaglandin production with expression of chemokines and chemotactic proteins that 
stimulate tissue leukocyte infiltration (ii); production of local vasoconstrictors, including 
endothelin (ET-1) and PGF2, leading to vasoconstriction (iii); subsequent development of 
local areas of hypoxia in the inner portions of the functional layer secondary to 
vasoconstriction, causing an increase in inflammatory reactivity (iv), as well as an 
upregulation of local matrix metalloproteinases (MMPs) that break down the extracellular 
matrix (ECM) (v). These changes achieve a controlled inflammatory response with a 
controlled amount of bleeding, while enabling regeneration of the tissue without scarring (4).  
In order for the endometrium to degenerate and regenerate itself, the blood supply must be 
controlled, including growth and proliferation of blood vessels. This process is called 
angiogenesis, and the endometrium is the only known adult human tissue in which 
angiogenesis occurs as a physiologic process (4).  
1.1.2 Endometrial angiogenesis 
The endometrial vasculature in the human body has been extensively studied due to its 
unique characteristics. The uterine artery, which is the main blood vessel supplying the 
uterus, branches and gives rise to the arcuate arteries of the myometrium. The radial arteries 
branch out from the arcuate arteries and give rise to two types of small arteries, the basal and 
spiral arteries of the myometrial-endometrial interface. The basal arteries supply the basal 
region of the endometrium, while the spiral arteries penetrate and vascularize the more 
superficial areas of the functional endometrial layer (5). 
The spiral arteries elongate, branch, and coil as the endometrium grows during the 
menstrual cycle. As the menstrual cycle progresses, they form a dense network of 
capillaries, known as the subcapillary plexus, located just below the epithelium. During the 
secretory phase of the cycle, coiling of the spiral arteries becomes more extensive.  
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Furthermore, the venous system develops concurrently with the arteries, and several smaller 
veins coalesce over the course of the menstrual cycle to form sinuses, which converge to 
form larger veins as they pass from the superficial into the deeper regions of the 
endometrium and ultimately the myometrium, where they drain into the uterine veins (6). 
Angiogenesis in the human endometrium occurs during all three phases of the menstrual 
cycle, and at different anatomical locations therein. During the bleeding phase, angiogenesis 
mainly occurs in the basal layer, during the proliferative phase in the functional layer, and in 
the secretory phase in the subepithelial capillary plexus.  In addition, mediation of 
angiogenesis differs between these phases (7). During the bleeding phase, angiogenesis in the 
endometrium occurs independently of sex hormone expression. Evidence for this comes from 
mouse models where rodents who underwent oophorectomy and subsequently had one 
menstrual cycle exogenously induced still managed to regenerate a new endometrial lining 
afterwards despite the lack of sex hormones. This suggests that angiogenesis that takes place 
during the bleeding phase is mainly under the control of locally produced endometrial factors 
(8). 
During the proliferative phase, angiogenesis is estrogen-driven since no new functional layer 
will grow in its absence and thereby no new vessels either. Evidence for this finding comes 
from studies on monkeys that underwent oophorectomy followed by estrogen and 
progesterone implants to mimic a normal menstrual cycle. Endometrium sampling showed a 
peak in endothelial cell proliferation markers during the mid-proliferative phase when the 
estradiol concentration was at its highest. Vascular generation was absent in monkeys without 
an estradiol implant (7).  
During the secretory phase, blood vessel growth decrease; instead, maturation with more 
coiling of spiral arteries and incorporation of mesenchymal cells into the vascular walls 
occurs. Some theories suggest that most of the maturation process is actually controlled by 
endometrial natural killer (NK) cells that modify growth of spiral arteries and mediate 
incorporation of mesenchymal cells into the vascular walls (9). Some studies using in vivo 
models have shown that a paucity of NK cells in the endometrium leads to increased 
mesenchymal cell recruitment into the vessels (10, 11). 
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The mechanisms by which sex steroid hormones exert control over growth of endometrial 
vessels on the cellular level is not understood, since endothelial cells lack both estrogen and 
progesterone receptors. The main hypothesis is that estradiol and progesterone exert their 
effect on endometrial angiogenesis through stimulation of other cells in the endometrial 
stroma, which in turn produce local factors that promote vessel growth and migration (12). 
Regulation of angiogenesis on the molecular level is a tightly controlled process where the 
balance between promoters and inhibitors will tip the vessels into either a pro- or anti-
angiogenic state. The paradigm that control of angiogenesis relies on a balance between 
promoters and inhibitors was first described by Judah Folkman et al., who discovered that 
primary tumor cells produce factors capable of promoting angiogenesis in their local vascular 
bed, while angiogenesis was inhibited in the vascular bed of metastases in the same patient, a 
process that may be explained by local differences in the balance between promoting and 
inhibiting factors. For angiogenesis to occur, an angiogenic switch must be in place where 
signals from promoters exceed those of inhibitors (13).  
Angiogenesis is often initiated by vasodilation of existing vessels with an increase in vascular 
permeability. The best known promoter of permeability and vessel growth is vascular 
endothelial growth factor A (VEGF-A). Induction of this factor has been demonstrated in 
areas of local hypoxia through stimulation by hypoxia-inducible factor-a (HIFa), but VEGF-
A has also been found around mature and stable vessels where angiogenesis does not occur, 
implying that VEGF-A is both an angiogenic promoter of and survival factor for vascular 
endothelial cells (14). VEGF-A promotes vessel growth by binding to the VEGF 1, 2 and 3 
receptor sites found on the endothelial cell surface, where they mediate an increase in 
vascular permeability through redistribution of cellular adhesion molecules such as PECAM-
1 and vascular endothelial cadherin. This increased permeability leads to leakage and 
extravasation of macromolecules and proteins, while also promoting endothelial cell 
migration, mitosis and division and preventing apoptosis (15).  Following extravasation of 
macromolecules and fluid, degradation of the ECM in the stroma takes place, which enables 
migration of new endothelial cells. Degradation of the ECM also liberates growth factors 
previously bound therein, such as bFGF, TGF-b and IGF-1, and subsequently stimulates 
endothelial cell migration into the tissue (16). 
Angiogenesis occurs through four different processes: sprouting (i), elongation (ii), 
intussusception (iii) and incorporation of circulating endothelial progenitor cells (iv). The 
new vessel is then stabilized through creation of a new basement membrane and recruitment 
of mesenchymal cells.  
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In smaller vessels and capillaries the recruited mesenchymal cells are usually pericytes, and 
in larger vessels smooth muscle cells, which enable the vessel to regulate contractility, blood 
flow and permeability (17). Regulation of vessel growth and the switch to vessel maturation 
is mediated by angiopoietin-1 (Ang1) and its binding to the tie-2 receptor (18). It is not 
known which of the four angiogenic processes is dominant in the endometrium. Markers for 
tip cells, a special cell involved in vessel sprouting, have not been found in isolated 
endometrial tissues, which may indicate that the endometrium instead uses the other three 
pathways to a higher extent during angiogenesis (19). To stabilize the newly formed vessel 
tubes, the endothelial cells produce PDGF-B and TGF-b to attract supporting mesenchymal 
cells. These cells migrate into the vicinity of the new basement membrane, where they help to 
build up the new basal membrane and support the endothelial cells. Vessels possessing a 
basement membrane and recruited mesenchymal cells are considered to be mature (20).  
Picture 3: Angiogenesis in the human endometrium (21) © 
Immunohistochemical studies have shown that endometrial VEGF-A is found in the luminar 
and glandular epithelium, with increased expression during the secretory phase compared 
with the proliferative phase. The principal receptor, VEGF-R2, is mainly expressed on 
endothelial cells in the endometrium during the proliferative phase with a second peak in the 
mid-secretory phase. These findings indicate that VEGF-A plays a crucial role for 
angiogenesis of the human endometrium (22). 
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 The effect that VEGF-A has on vascular permeability also increases expression of 
prostaglandins and nitric oxide in the endometrium, both of which are known to be 
vasodilators and chemotaxins for immune cells (21).  
1.1.3 Cancer inheritance 
The first description of biological inheritance of traits can be traced back to Moravian monk 
Gregor Mendel, who discovered that the color of his flowers could be predicted by imagining 
that the two parent flowers each passed on two copies of the same trait, which could be either 
dominant or recessive. After the discovery of DNA and subsequent whole genome 
sequencing, we now know that what Gregor Mendel described was two gene variants, alleles, 
of the same gene that coded for pigment in his flowers. In the case of a dominant allele, only 
that gene is used for mRNA transcription and protein synthesis, while the recessive allele 
remains dormant, unless both copies are of the recessive allele, which would then result in the 
color of the recessive phenotype in that flower. To better describe this phenomenon, 
biologists use the term autosomal dominant inheritance for phenotypes in which one 
dominant allele copy found on one of the non-sex chromosomes is sufficient to produce that 
phenotype, whereas autosomal recessive inheritance require two copies to do so.    
In the case of known cancer syndromes, where a mutation in one specific gene increases 
cancer risk, the rule is that there is only one mutated allele from one parent, and one normally 
functioning allele from the other. This differs from Mendelian inheritance since the healthy 
allele initially functions as the dominant allele, and results in a normal phenotype for that 
individual during the first decades of life. However, should the healthy allele acquire a 
somatic mutation later in life from environmental damage to the DNA or by coincidence, 
there would be no normal backup and the cell would become susceptible to developing 
cancer. This is called the two-hit hypothesis (23), and explains how inherited cancer 
syndromes can have an autosomal dominant pattern of inheritance clinically, but requires two 
non functioning alleles on the cellular level in order for the cancer phenotype to be displayed 
(24). Many of the known cancer syndromes have mutations in genes that code for the proteins 
that are responsible for repairing and protecting the DNA strand during and after DNA 
replication. 
 
 
 
 8 
1.1.4 Proofreading of DNA 
DNA proofreading is a three-step process, occurring at different times during replication. The 
first proofreading step is carried out by DNA polymerase. Since attachment to the correct 
base pair is energetically more favorable, the affinity of polymerase to incorporate a correct 
new base is higher. Once the nucleotide bases have become attached, the polymerase must 
tighten its grip around the chain to facilitate covalent bonding of nucleotides to the skeleton 
of the chain, after which the polymerase can proceed to the next base pair. The entire process 
is also more efficient when correct base pairs become attached (24, 25). 
Exonuclease is responsible for the second proofreading. The mode of action is dependent on 
the fact that DNA polymerase will not add another base to the daughter chain if the most 
recently attached base does not display a 3’-OH tail onto which the next base can attach. For 
DNA replication to continue, the exonuclease will remove the latest inserted base on the 
daughter strand until a 3’-OH tail is displayed on the active site of the polymerase, which can 
then continue to add a new base (26). 
Picture 5: The MMR system and its recognition of mismatch errors in the DNA-strand (27) © 
The Mismatch-repair (MMR) system carries out the third and final proofreading once DNA 
strand replication is complete. The process by which this occurs was discovered in mutant 
bacteria that lacked functional exonuclease, but surprisingly had a lower than expected 
mutation rate. The system recognizes sites of potential strand distortion that occur around 
incorrectly matched base pairs where they form a nick in the DNA strand. The system must 
also distinguish between the daughter strand and the parent strand, since it would otherwise 
correct the wrong strand in 50% of cases, thereby creating mutations at the same rate.  
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Eukaryotic cells contain natural single strand breaks in the daughter strand that are 
subsequently sealed by DNA ligase. MMR probably relies on these strand breaks as a 
recognition marker for the daughter strand. However, this theory only explains recognition of 
the lagging daughter strand, thereby implying that single strand breaks must be created in the 
leading daughter strand since it does not acquire them naturally in the replication process 
according to current knowledge, but the underlying mechanism is unknown (28). 
1.2 Clinical diagnosis 
1.2.1 Heavy menstrual bleeding (HMB) 
About 20-30% of women of reproductive age experience excessive menstrual bleeding, 
known as heavy menstrual bleeding (HMB) (29). HMB has traditionally been defined as 
menstrual bleeding in excess of 80 ml per menstrual cycle (30). HMB is the fourth most 
common cause for gynecological referral in the developed world (31). A national cost 
estimate for diagnostics, treatment and supportive care for HMB in the UK in 2000 was 
approximately GBP 65 million. 
The etiology of HMB can be subdivided according to the PALM-COEIN classification 
system, an acronym that stands for polyp, adenomyosis, leiomyoma, malignancy, 
coagulopathy, ovulatory, endometrial, iatrogenic, and not yet classified (32). The PALM 
diagnoses can be made based on imaging studies or tissue biopsies, while the COIEN 
diagnoses are attributable to causes that cannot be imaged or diagnosed based on 
histopathology (32).  HMB may present at any time during a woman’s reproductive years and 
during any phase, both ovulatory and anovulatory, of the menstrual cycle, depending on its 
etiology (31). HMB prevalence increases with age because of the higher incidence of 
anovulatory cycles as women approach menopause. An estimated one of three women suffers 
from HMB during perimenopause (33). Women who develop HMB later in their 
reproductive life have secondary HMB, while women suffering from HMB from the time of 
menarche have primary HMB (31).  
The clinical challenge when assessing HMB, aside from identifying the underlying cause, is 
to measure actual blood loss during the menstrual cycle. The gold standard for this 
determination is the alkaline haematin method in which all soiled sanitary products are 
collected and incubated, after which conversion of hemoglobin to haematin is measured with 
a spectrophotometer to provide an estimate of blood loss (34). For obvious reasons this 
method is difficult to use in everyday clinical practice. 
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Instead, the Pictorial Blood Assessment Chart (PBAC) is used, where patients themselves fill 
in the number of sanitary products and degree of blood soiling, based on which an estimate of 
blood loss can be calculated. A score of >100 on the PBAC has a sensitivity of >80% for 
HMB (35). Although not strictly objective, the simplicity and affordability of the PBAC have 
made it the most commonly used tool to measure blood loss in HMB.  
 
Picture 4: The PBAC. A score >100 during a menstrual period is considered to be diagnostic for HMB (36). 
Clinical management of women with HMB depends on the underlying cause, but some 
pharmacological and surgical tools can be used for all HMB to reduce blood loss regardless 
of etiology. Pharmacological treatment can be further subdivided into hormonal or 
hemostatic.  
Hormonal treatment includes progestin-releasing intrauterine systems, combined oral 
contraceptives, cyclical oral progestogens or progestin-only contraceptives. The main 
mechanism by which these treatments function is to increase progesterone activity on the 
endometrium, which stabilizes the growth of tissue as previously described. Many studies 
have shown that these treatments are generally effective at reducing blood loss, especially in 
intrauterine systems, where a 70% reduction in PBAC score is seen in the first three months 
of use, with a sustained effect after four years in a large randomized control study (37).  
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Intrauterine devices have been proven to be more efficacious than oral contraceptives in 
decreasing blood loss and are usually well-tolerated by patients (38, 39), although hormonal 
side effects may occur, including irregular spotting, breast tenderness and pain (36). 
However, this approach is not an option for women who wish to become pregnant.  The most 
commonly used hemostatic treatment for HMB is tranexamic acid, which prevents 
fibrinolysis of blood clots. A large meta-analysis of tranexamic acid treatment used for 5 days 
showed a reduction in blood loss during the menstrual period ranging from 34-56% (37). 
Surgical treatment of HMB is usually reserved for women who do not achieve an adequate 
response to the pharmaceutical options described. Surgical intervention for HMB is quite 
common; for example, the rate of surgical treatment for HMB was 14.3 out of 10 000 women 
in the UK in 2009 (40). Alternative surgical treatments include endometrial ablation or 
hysterectomy. Ablation technique has improved over the years, with fewer complications and 
less need for secondary ablations later on (41). It should be noted, however, that a 
comparison between ablation and intrauterine contraceptive devices has shown no significant 
benefit in long-term outcome for treatment of HMB (42). Hysterectomy is the definitive 
treatment when all other options have failed. In recent years, the number of hysterectomies 
for HMB has dropped due to improved first-line treatments. For example, in the UK the 
number of hysterectomies for HMB decreased from 20 000 in 2000 to 7000 in 2005, which is 
in line with the current rate for this procedure (43). 
1.2.2 Endometrial cancer (EC) 
Endometrial cancer (EC) is the most common cancer of the female reproductive tract in the 
developed world with an age-standardized incidence rate of 13.6 per 100 000 women in 2012 
in Europe (44). EC usually occurs in postmenopausal women; more than 90% of cases are 
diagnosed after age 50 with a median age of 63 years, although 4% of cases occur prior to age 
40 (45). Because most cases are diagnosed in response to occult postmenopausal bleeding, 
the majority of patients are diagnosed at FIGO stage I, with an excellent five-year survival 
rate (>95%), when surgery is the only treatment necessary. However, survival rates decrease 
when there is regional spread or metastatic disease, associated with five-year survival rates of 
68% and 17%, respectively (44). Worldwide, there are approximately 74 000 deaths per year 
from this disease (46). 
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The old classification system divided EC into two different subtypes based on 
histopathological appearance; type I was known as endometroid EC, while type II was based 
on histology of non-endometroid origin such as serous, clear cell, and undifferentiated 
tumors. Recent advances in tumor biology now enable classification of EC tumors into four 
different groups based on biological tumor characteristics; 1) POLE (ultramutated) tumors, 2) 
MSI (microsatellite instability) tumors, 3) TP53 mutated tumors, and 4) remaining tumors. 
The new classification system correlates better with tumor behavior and long-term prognosis 
(47). 
Many known environmental risk factors have been linked to EC, all of which are associated 
with higher exposure of endometrial tissue to estrogen. The best known risk factor is obesity, 
with a relative risk of 2.21 in obese women compared with controls, found by a large meta-
analysis (48). Additional risk factors associated with higher estrogen exposure and thereby 
higher risk of EC include nulliparity, early menarche, late menopause, estrogen hormone 
treatment and polycystic ovary syndrome (49).  
EC due to genetic predisposition is a well-established phenomenon linked to germline 
mutations in the MMR genes, the most common of which is Lynch Syndrome (LS). Other 
germline mutations that increase risk of EC include mutations in the BRCA1/BRCA2, PTEN, 
ATM and CHEK2 genes (50). Based on data obtained from unselected cases of EC, it is 
believed that approximately 10% of all ECs result from one of these germline mutations, with 
LS being responsible for approximately 5% of all EC cases. What clinically sets LS apart 
from other germline mutations is earlier age at diagnosis, with half of all LS-associated EC 
tumors detected before age 50, and location within the lower uterine segment (LUS) to a 
higher extent (50). 
1.3 Angiogenetic factors in endometrial disease 
1.3.1 Known angiogenetic factors in HMB-E 
A study by Kooy et al. observed an increased proliferation of endometrial cells in HMB-E 
compared with controls, suggesting an imbalance in angiogenic factors within the 
endometrium (51). Other studies have shown a lower number of mesenchymal cells 
surrounding microvessels in HMB-E. Moreover, a previous study by Mints et al. showed that 
small endometrial vessels demonstrate abnormal morphology in HMB-E, with an increase in 
number and size of endothelial cell gaps lining the vascular lumen (52).  
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This lack of maturation has been hypothesized as a possible explanation for HMB-E since a 
lack of contractile cells surrounding the vessels would lead to an inability to restrict blood 
flow when needed and might prevent the distal hypoxia necessary for the shedding process 
(53). Abnormal activation of MMPs and their tissue inhibitors of metalloproteinases 
(TIMPs), which could impair the controlled breakdown of endometrial tissue during 
menstruation, has been observed in women with HMB-E (54). Other studies of women with 
HMB-E have also shown down-regulation of Ang-1, which could affect maturation of vessels 
(55). 
Yet other studies have shown that the ratio between vasoconstrictors and vasodilators is 
altered in HMB-E, with an increase in the vasodilators PGE and VEGF-A, while there is also 
a lack of vasoconstrictors such as PGF and ET-1 in the endometrium of women with HMB-E 
(56). It is not yet clear whether all of these changes occur in all cases of HMB-E, or whether a 
single imbalance is sufficient to alter control of menstrual bleeding, nor has the actual 
underlying etiology for HMB-E been determined. 
1.3.2 Known angiogenetic factors in EC 
In order for a tumor to grow to a size greater than 1-2 mm it must develop new blood vessels. 
These vessels are important for metastasis of the tumor at a later stage. The most extensively 
studied angiogenic factor in cancer in general and in EC in particular is VEGF-A. VEGF-A is 
overexpressed in about 2 out of 3 EC tumors, and a higher level of expression correlates with 
greater likelihood of metastasis and poor clinical outcome (57-59). Because it is known that 
VEGF-A is overexpressed, especially in advanced disease, VEGF inhibitors have been 
studied in trials and used in the clinical setting for patients with advanced EC, but 
unfortunately a high number of tumors become resistant to this treatment (60). Some studies 
also recommend VEGF-A as a serum marker in advanced EC to monitor the effects of 
chemotherapy (61).  A new approach in recent trials is to inhibit VEGF-A and certain 
additional axes in endometrial angiogenesis, such as the mTOR intracellular protein, which is 
known to be a key regulator for activation of HIF-a (62).  
Other angiogenic factors that have been studied and correlated to tumor stage in EC include 
MMPs 2 and 9, which are also involved in the physiological breakdown of the endometrium 
during menstruation. Both MMPs are independently involved in angiogenesis and metastasis 
in EC, but which of them plays the more significant role remains controversial (61). It is 
known that both MMPs are usually overexpressed in EC tumors in general, and in type I 
tumors in particular (63), although the significance of this overexpression is unclear.  
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Some studies have reported one or the other of them to be poor diagnostic markers of 
histologically poorly differentiated tumors and aggressive tumor invasion respectively (64, 
65) while others have found them to correlate with clinical outcome but not with tumor 
differentiation or invasion (66). Recruitment of epithelial progenitor cells (EPCs) from the 
bone marrow and bloodstream has also been shown to be essential for growth of tumor 
microvessels (67).  
1.3.3 SDF-1 and angiogenesis 
Stromal Cell-derived factor-1 (SDF-1) (or CXCL12) is a chemokine that binds to the CXCR4 
receptor on target cells. SDF-1 is most abundant in the ECM in liver, spleen, pancreas and 
heart, but is found in all human tissues (68). The SDF-1/CXCR4 signaling axis is known to 
be of central importance in preserving the hematopoietic stem cell niche (69) and to act as a 
homing beacon for blood cells to the bone marrow (70). In peripheral tissues CXCR4 has 
proven to be the most expressed chemokine receptor on endothelial cells, and the interaction 
with SDF-1 is fundamental to angiogenesis since knocking out one or both factors in mice 
results in a lack of vessels, especially in the gastrointestinal tract (71). Studies have also 
shown that expression of CXCR4 can be upregulated by other angiogenic factors such as 
VEGF-A, TNF-a and bFGF, ultimately making the cells more sensitive to SDF-1 (72). The 
observed effect on endothelial cells after SDF-1 exposure is to increase production and 
release of angiogenic factors (VEGF-A and bFGF), which ultimately leads to a positive 
feedback loop with a further increase of production of CXCR4 and SDF-1 in the endothelium 
(73). It has been suggested that this positive feedback loop is important for maintaining 
endothelial structure and survival during angiogenesis. A growing body of evidence has 
found that SDF-1 plays an essential role in vascular injury and in recruitment of progenitor 
cells from the bloodstream to injured tissue. This is done through upregulation of cellular 
adhesion molecules (CAMs) on the endothelial cells and selectins present on the vascular 
endothelium of the injured tissue (74).  
The properties associated with the SDF-1/CXCR4 axis have been shown to be vulnerable to 
hijacking by pathological processes, especially cancer where SDF-1 overexpression is usually 
a negative prognostic factor (75). First of all, the feedback loop between VEGF-A and SDF-1 
signaling creates a strong angiogenic signal in areas of local hypoxia, resulting in more 
efficient recruitment of new vessels to these parts of the tumor, while the ability of SDF-1 to 
attract and keep ECs in the surrounding tissue helps to preserve the structure of the vessels as 
the tumor expands (76). 
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1.3.4 Endothelial progenitor cells (EPCs) 
EPCs are phenotypically defined as a cell population expressing CD133, CD34 and VEGFR2 
surface markers, although this definition is currently under debate (77). Previously, it was 
believed that this cell population originated exclusively from the bone marrow, but recent 
evidence shows that these cells can also originate from nonhematopoietic tissues such as 
liver, spleen and adipose tissue (78). When a vascular injury is signaled, these cells are 
released into the bloodstream and incorporated into vascular walls, where they mature into 
endothelial cells (79). Recruitment of EPCs to sites of vascular injury has been demonstrated 
to result from signals of local hypoxia, which induce increased production of SDF-1 in the 
injured tissue. SDF-1 then travels through the bloodstream to the bone marrow, where it 
enables release of EPCs into the bloodstream (80). Therefore, binding of SDF-1 to the 
CXCR4 receptor on the EPCs is essential for attracting EPCs to the injured tissue (81). 
During the maturation process of EPCs into ECs with incorporation into the vascular wall, 
they secrete proangiogenic factors that ultimately result in vessel growth with resolution of 
local hypoxia. This ability of SDF-1 and EPCs to respond to local hypoxia have made them a 
promising target for medical treatment of cardiovascular disease, but unfortunately without 
long-term clinical effect, mainly because of an inability to mimic physiologic recruitment of 
EPCs into the hypoxic tissue (82). Exactly how the EPCs are recruited to the endometrium is 
not completely clear, although some studies have shown that estrogen and progesterone have 
a stimulating effect on EPCs. A study by Matsubara et al. measured the number of EPCs 
cultured in vitro from peripheral blood taken during the bleeding, proliferative and secretory 
phases, which showed a significantly higher number of cultured EPCs in bleeding phase 
blood stimulated with estrogen and progesterone (83). Furthermore, additional studies have 
demonstrated that estrogen and progesterone stimulate EPC recruitment and survival, an 
effect which also seems to be mediated by the SDF-1/CXCR4 axis (84-86). 
1.3.5 The pericyte 
The pericyte was first discovered in 1873 as a cell that was wrapped around capillary vessel 
walls (87).  Pericytes are indeed present in smaller arterioles and capillaries, but are mostly 
found in post-capillary venules. Pericytes display filaments with contractile properties such as 
alpha-smooth muscle actin (aSMA), a similarity shared with smooth muscle cells, although 
some characteristics set them apart, such as pericyte attachment along the longitudinal axis of 
the vessel with multiple extensions into the cytoplasm of the basement membranes or directly 
into the endothelial cells (88).  
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Pericyte coverage varies greatly among different tissues. In the capillaries of the central 
nervous system, there is a 1:1 ratio between endothelial cells and pericytes, while the ratio is 
approximately 1:100 in peripheral tissues, such as smooth muscle, indicating a role in vessel 
barrier function (89). The lifetime of endothelial cells in any given tissue correlates with 
pericyte coverage; higher coverage is associated with longer lifetime, indicating the 
importance of the support role to endothelial cells (90). A difference in pericyte coverage can 
also be found between the lower and upper body, with higher coverage in the lower body, 
indicating a regulatory function on blood pressure at the capillary level (89).  
Pericytes have been shown to play an active role in the process of angiogenesis. First of all, 
these cells have the ability to produce and secrete MMPs that help to degrade the basement 
membrane and surrounding tissue, thereby enabling new vessels to sprout (91). When new 
EC tubes penetrate new tissues, they are unstable with low barrier integrity. The new ECs 
then secrete PDGF-b, which attracts pericytes to the new vessel, thereby initiating 
construction of a new basement membrane and ultimately stabilization of the vessel (92, 93). 
Meanwhile, the newly recruited pericytes begin to secrete inhibitory angiogenic factors such 
as TGF-b and Ang-1, which stops angiogenesis once vessel maturation has been achieved 
(35). In vivo studies on diabetic retinopathy have shown that one of earliest signs of 
dysfunctional vascular integrity, even before formation of pathological vessels, is a 
significant loss of pericytes (94). Just how local hyperglycemia leads to pericyte loss is not 
fully understood, but it is known that levels of PDGF-b in the retina decrease, while Ang-2 
levels increase (95, 96), both of which act as a proangiogenic signal, while also inhibiting 
pericyte recruitment and vessel maturation. In conclusion, all evidence points to the pericyte 
as a key player in angiogenesis and even more importantly in the next step of the process 
where vessel maturation needs to occur.     
1.4 Hereditary factors in endometrial disease 
1.4.1 Hereditary HMB-E 
Some past studies have looked for a genetic predisposition for developing HMB-E. The first 
study by Sneider et al. found that the rate of hysterectomies for the indication of HMB-E was 
higher among first degree relatives of women who also underwent surgery for HMB-E (97). 
A subsequent study found high clinical overlap between the diagnosis of HMB-E and family 
history of HMB-E among first degree relatives (98). 
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The reason for these findings has not yet been studied. Results from studies on excessive 
angiogenesis in diabetic retinopathy have shown a link between certain polymorphisms in the 
VEGF-A gene and risk of developing retinopathy given similar blood sugar control, which 
indicates that inherited differences in the VEGF-A gene may play a crucial role in whether 
angiogenesis is physiological or pathological (99, 100). 
1.4.2 Lynch Syndrome (LS) 
LS, also called HNPCC, was first described in 1966 by Henry Lynch when he detected a 
hereditary pattern for cancer in two large families with strikingly similar carcinomas that 
developed at an unusually early age for cancer and demonstrated a clear autosomal 
dominant pattern of inheritance. Carcinomas of the colon and the endometrium were the 
most commonly found diseases in these two families (101). Today it is known that patients 
with LS are at increased risk of malignancy in various tissues, including colon, 
endometrium, stomach, small bowel, biliary tract, pancreas, urinary tract, bladder, ovary, 
brain, prostate and breast (102). 
Genetically, four different mutated genes comprise the clinical syndrome, in which one 
mutation singlehandedly causes the Lynch phenotype with varying degrees of susceptibility 
for different cancers. The four genes are MLH1, MSH2, MSH6  and PMS2. These genes 
code for the proteins involved in single-nucleotide repair of DNA during cell replication 
known as the MMR-system which function has been previously described. The DNA in 
affected cells will eventually display MSI due to an inability to correct the single nucleotide 
errors that are constantly acquired during DNA strand replication, thereby leading to an 
accumulation of additional single nucleotide base pairs at certain loci in the genome which 
are referred to as microsatellites (103). Individuals who inherit the trait for this cancer 
syndrome usually have only one mutated gene copy (allele) from one parent, and one 
functioning allele from the other. However, if the healthy allele develops an acquired 
somatic mutation the cell lineage will display the hazardous phenotype, following the rule 
of the two-hit paradigm, which has also been previously described (23). 
1.4.3 Clinical and laboratory screening methods for LS 
Clinical screening for LS is based on the Amsterdam II (AmII) and revised Bethesda Criteria. 
These criteria have been updated since previously they did not take cancers other than 
Colorectal Cancers (CRC) into consideration, and therefore lacked sensitivity to other cancers 
associated with the syndrome.  
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All AmII criteria must be met in order for the patient to be considered positive and a 
candidate for germline gene testing of MMRs to determine LS status. Concerning the 
Bethesda criteria, fulfilling one criterion is sufficient to pursue further laboratory studies to 
confirm an MSI tumor as a next step, and if positive, to continue with further testing of 
germline DNA. 
Amsterdam II (Am II): 
1. Three or more relatives with an LS associated cancer (CRC, EC, small intestine, 
ureter or renal pelvis etc) 
2. Two or more successive generations affected  
3. One or more relatives diagnosed before the age of 50 years  
4. One should be a first-degree relative of the other two 
5. FAP should be excluded in cases of colorectal carcinoma  
6. Tumors should be verified by pathologic examination (104) 
 
Revised Bethesda criterias 
1. Colorectal or uterine cancer diagnosed <50 years of age 
2. Presence of synchronous or metachronous LS associated cancers regardless of age 
3. CRC with MSI-histology in a patient <60 years of age 
4. CRC diagnosed in one or more first-degree relatives in a patient with a LS-associated 
tumor, with one of the cancers being diagnosed before 50 years of age. 
5. CRC diagnosed in two or more first or second degree relatives in a patient with a LS-
associated tumor regardless of age (105).   
 
However, 25% of LS-carriers presenting with their first tumor will not meet the Am II criteria 
at the time of diagnosis, which makes these patients easy to miss (106), and only 54% of LS-
carriers with EC meet the Am II criteria. Patients presenting with EC as their first cancer 
(sentinel cancer) are especially easy to miss (107). The sensitivity of the Bethesda criteria is 
higher at approximately 90%, but their positive predictive value is only 3-5% because of the 
many false positives (108). Because of this limitation in clinical screening, many recent 
studies have attempted to implement universal laboratory screening for EC in order to 
improve the detection rate. The primary pathological screening method currently in use is 
immunohistochemistry (IHC) on MMR proteins in the tumor. When MLH1, MSH2, MSH6 
and PMS2 antibodies are used simultaneously, IHC has 91% sensitivity and 83% specificity 
for detection of MMR protein loss (109, 110).  Confirmed MMR protein loss or MSI-H 
tumor together with one positive Bethesda criteria have a positive predictive value of 25-30% 
for finding an LS mutation in the germline DNA (108). 
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The second option is determination of MSI by PCR analysis, which strongly correlates with 
IHC testing. Depending on the number of microsatellites the PCR detects, the answer will be 
either microsatellite stable (MSS) which means no instability at all, or microsatellite low 
(MSI-L) meaning that there are some but few microsatellites, or microsatellite high (MSI-H) 
which means that the tumor displays a MSI phenotype.  
1.4.4 LS associated EC 
Henry Lynch described the high susceptibility for EC in female family members of LS 
patients in the first paper in which he described LS syndrome. Lifetime risk for EC in the 
general female population is approximately 2.6%, while EC risk in LS ranges from 42% to 
54%. EC associated with LS accounts for 2.5-5% of all EC tumors. The incidence of EC in 
the general population rises with age until age 70, after which it steadily declines. The ages 
in the Lynch group are different; mean age at diagnosis is 48 years and over 50% of all 
patients are diagnosed before age 50 (111).  
 
Studies of the various genes involved in LS show clear differences in EC risk associated 
with different genes, as well as different mean ages at diagnosis. The lifetime risk of EC 
associated with the MSH6 mutation is 64-71%; MSH6 mutation carriers are most prone to 
develop this malignancy. The lifetime risk for EC in MLH1/MSH2 varies between 40-50%. 
Mean age at time of diagnosis of EC also varies between 48-51 years for MLH1/MSH2 and 
56-62 years for MSH6 (109).  
 
Histological classification of EC tumors is the same in the LS group as in sporadic cases of 
EC; 80% are endometroid and 20% non-endometroid. However, the histopathological 
features of ECs related to LS are usually more diverse than those seen in sporadic tumors 
and may include both endometroid and non-endometroid malignant histology within the 
same tumor. MSI-H status correlates with an increase in: mucinous features, signet ring 
cells, number of tumor-infiltrating lymphocytes and inflammatory activity at the tumor 
periphery (112). Moreover, LS tumors are more likely to involve the LUS (111) and 34% of 
LUS ECs demonstrated MSI-H, while 29% of these MSI-H tumors were associated with a 
LS mutation, as reported in a study of EC involving the LUS linked primarily to MSH2 
mutations (50).  
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Currently, the National Comprehensive Cancer Network (NCCN) in the US recommends 
that LS testing be considered in all patients under the age of 55 diagnosed with EC, 
regardless of clinical criteria fulfilment. Many centers already screen for LS on all CRC 
tumors newly diagnosed before age 60 using IHC for MMR protein loss without 
undertaking further clinical triage of patients, but not on ECs routinely (113). 
1.4.5 Additional hereditary factors in EC 
LS is the best-known hereditary cancer syndrome linked to a high incidence of EC. As 
previously mentioned, there are other cancer syndromes in which the incidence of EC is 
higher than in the normal population. Once these known mutation carriers are excluded from 
the EC population, researchers still observe a twofold increase in risk of developing the 
disease among women with a family history of EC in a first or second-degree relative 
compared with the remaining female population without a family history of EC (114). 
This over-representation cannot fully be explained solely by environmental factors such as 
obesity and estrogen exposure, which would probably have a more equal effect on the entire 
female population. Nor is there a linear relationship between incidence of EC and incidence 
of obesity, as would be the case if the increased incidence of EC depended solely on 
increased obesity (115). These observations suggest that other hereditary factors are involved 
in development of EC, not just single gene mutations or environmental risk factors. Certain 
single nucleotide polymorphisms (SNPs) in the genes involved in estrogen production, 
signaling and degradation have already been found to be associated with EC risk, such as in 
the genes ER-a, CYP17A1 and CYP 19A1 (116-119). Recent Genome Wide Association 
Studies (GWAS) (120-122) analyzing SNPs have already identified several EC risk loci in 
the human genome. These taken together explain <5% of relative family risk for EC 
development, but it should be noted that most of these studies were conducted in 
heterogeneous populations, which makes it more difficult to draw conclusions on how much 
overrepresentation of single SNPs contribute to cancer risk in the next generation of a 
homogenous population. Therefore, many current GWAS are based on analysis of haplotype 
instead.  
Haplotypes can be described as a specific consecutive combination of SNPs found in close 
proximity to each other on a chromosome; they are preserved through many generations 
because they are not usually affected by large relocations of the genome during homologous 
recombination cycles. This is why haplotypes are often used as markers for ethnicity (123).  
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Haplotypes in close proximity to genes that are known to be involved in EC development 
have already been found, which helps explain the differences in EC risk between different 
ethnicities (118, 124, 125).  Other GWAS have also found certain variations in gene loci 
within the HNF1B and TERT-CLPTML1 genes associated with an overall increased risk of 
cancer, including for EC (126, 127). 
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1.3 Aims 
1.3.1 General aims of the thesis 
The overall aim of this thesis is to contribute knowledge about the hereditary and 
angiogenic endometrial factors involved in both HMB-E and EC.  
 
This has been done by investigating the cellular and molecular processes of endometrial 
angiogenesis that are involved in HMB-E, as part of a search for further evidence in support 
of HMB-E as a disorder of angiogenesis. The hereditary aspects of EC were investigated by 
examining a known high-risk group of women (LS carriers) and also by assessing cases 
from the EC population at large with a family history of EC, but without hereditary cancer 
syndrome, all of which could help to reveal new genetic risk markers for the disease. 
1.3.2 Study I: aims 
The aim was to investigate whether levels of stromal cell derived factor-1 (CXCL12), and 
numbers of circulating EPCs, EPC colony-forming units (EPC-CFU) and mature endothelial 
cells differ between women with HMB-E and controls, and whether there is any correlation 
between these and plasma levels of other known angiogenic growth factors. The results could 
explain the importance, if any, of EPCs to angiogenesis in the endometrium. 
1.3.3 Study II: aims 
The objective was to conduct a prospective clinical study to investigate whether endometrial 
capillaries and microvessels in patients with HMB-E have less vascular pericyte coverage and 
thereby increased vascular fragility, and whether there is any correlation between pericyte 
coverage and expression of VEGF-A in endometrial vessels. The results may elucidate 
whether or not alterations in vessel maturation cause HMB-E.  
1.3.4 Study III: aims 
The purpose of this study was to assess the diagnostic modalities for gynecological screening 
of LS patients used in Sweden today and the clinical outcome achieved thus far using a 
retrospective study approach. The study could show whether screening visits are important 
for prevention of higher stage cancer and what diagnostic tools to recommend. 
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1.3.5 Study IV: aims 
The aim of this study was to investigate a Swedish population group to determine whether 
there is an overrepresentation of certain haplotypes within the genome of patients with EC 
who have a family history of EC but not hereditary cancer syndrome. The results could help 
to explain the higher incidence of EC in certain populations and to more effectively predict 
and prevent EC in the future.  
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2. METHODS 
2.1 Study I 
2.1.1 Study design, population and data collection 
Patients and controls were enrolled consecutively to avoid selection bias. The diagnosis of 
HMB-E was based on an accurate bleeding history and the pictorial blood loss assessment 
chart, where a score of >100 ml was considered to be HMB-E.  Women in the control group 
were selected based on the pictorial blood loss assessment chart, where a score of <80 ml was 
defined as normal menstruation. To exclude intrauterine pathology, all participants were 
required to have a normal transvaginal ultrasound (TVUS) and gynecological examination. 
Blood samples from the HMB-E patients were tested for platelet count, APTT, INR and 
bleeding time to exclude coagulation defects. 
Ten healthy control women and ten HMB-E patients, all of whom had regular menstrual 
cycles (25-32 days) and no hormonal contraception within three months prior to study start, 
provided four blood samples during a single menstrual cycle: two in the proliferative phase, 
one at ovulation and one in the secretory phase. The phases of the menstrual cycle were 
determined by using the first day of menstruation as the starting point, and by measuring the 
estradiol and progesterone levels in the blood samples obtained. The day of ovulation was 
determined by a urine test for luteinizing hormone (LH). The first blood sample was collected 
on day 1-2, the second on day 5, the third on the day of ovulation (day 14) and the fourth on 
day 22-24. First, the blood samples were used to isolate peripheral blood mononuclear cells 
(PBMCs) and to culture EPCs, after which the remaining blood was centrifuged (1000g) for 
15 minutes and the plasma was then frozen at -70 C before conducting an analysis.  
Plasma from all four samples was analyzed to measure levels of SDF-1, VEGF-A and bFGF, 
as well as granulocyte and granulocyte-macrophage colony stimulating factor (GM-CSF) 
using ELISA (R&D systems, Minneapolis, USA), all according to manufacturer instructions.  
A kinetic microplate reader, with an intra-assay coefficient ranging between 3-9%, measured 
the growth factor level on a single plate for each growth factor tested. 
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2.1.2 Flow cytometry and cell culture  
To determine PBMC phenotype for selection of EPCs, the flow cytometry test used an array 
of antibodies targeting specific markers for EPCs (VEGFR-2, VEGFR-1,Tie-2, CD133, 
CD146 and CD34), as well as markers for mature circulating ECs (CD141, CD144 and 
CD31). Homeostatic regulating molecules, including vascular adhesion protein-1 (VAP-1), 
CD142, heparin sulfate proteoglycan (HSP) and plasminogen activator inhibitor-1(PAI-1)), 
were also targeted in the flow cytometry test. The following antibodies used were for the 
test: anti-VEGFR-2, anti-CD141, anti-PAI-1, HSP (Biogenesis Ltd, Poole, UK), (Reliatech, 
Mascheroder, Germany), anti-VAP-1 (Serotec, Dusseldorf, Germany), anti-VEGFR-1 
(R&D Systems), anti-CD133 (Miltenyi Biotec, GmbH, Bergisch, Germany), Tie-2, CD34, 
CD144, CD31 and CD142 (Becton Dickinson, San Jose, CA, USA). To determine non-
specific binding of monoclonal antibodies, corresponding control isotypes were used. The 
test was conducted using a fluorescence-activated flow cytometer (FACSorter, Becton 
Dickinson). 
 
The PBMCs found in the flow cytometry test were then cultured on fibronectin-coated (20 
mg/ml) tissue culture plates in an endothelial-selective medium (EndoCult, Stem Cell 
Technologies, Vancouver, BC, Canada). The incubator had the following settings: 78.09% 
nitrogen, 20.95% oxygen, 0.93% argon, 0.039% CO2, 37C, and 95% humidity. On day 2 of 
culturing, the non-adherent cells were collected from the initial plates and placed in a 
second set of fibronectin-coated plates. The final CFU count on both sets of plates was 
done on day 5. 
 
2.1.3 Statistics 
For statistical analysis the non-parametric Wilcoxon matched pairs test was used to 
compare growth factor levels and number of CFUs between plates and at different time 
points. The Friedman non-parametric test was used to test differences between repeated 
estimates. Analysis was performed using SPSS software version 18.0, with P<0.05 
considered to be significant. 
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2.2 Study II 
2.2.1 Study design, population and data collection 
A total of 17 women with a normal menstrual cycle and a history of HMB for <5 years, and 
10 healthy women with a normal menstrual cycle who did not use hormonal contraception 
during the last three months were consecutively recruited from an outpatient clinic for women 
with HMB. Women with a pictorial blood loss score >100 ml were considered to have a 
diagnosis of HMB, while women with a score <80 ml served as controls. All study subjects 
underwent TVUS, as well as blood tests for platelets, INR, vWF and APTT to exclude uterine 
pathology and coagulopathy, after which a diagnosis of HMB-E could be made. The HMB-E 
patients in the study were also examined by hysteroscopy to rule out abnormalities.  
Blood samples and endometrial biopsies were obtained from each patient at the same time, 
along with a history concerning the number of days since the last menstruation. Blood 
samples were analyzed for estradiol and progesterone to help determine the phase of the 
menstrual cycle. Study subjects provided a urine dipstick LH test to determine the day of 
ovulation.  
This showed that 8 patients and 5 controls were in the proliferative phase, and 9 patients and 
5 controls were in the secretory phase on the day of biopsy. 
2.2.2 Immunohistochemistry and pericyte quantification 
The functional endometrial layer in the biopsy specimen was stained. Endothelial tissues 
embedded in 5 µm of paraffin were stained with antibodies to CD34 (Cat. no. ABIN343723; 
QBEnd/10; BioGenex, San Ramon, CA, USA) and a-SMA (SMAα; M0874; with a FITC 
conjugated IgG2a; Dako, Glostrup, Denmark) to identify endothelial cells and pericytes, 
respectively. We used Alexa 488 (I36933) or Alexa 568 (Z-25006; Molecular Probes, 
Eugene, OR, USA) as secondary antibodies, respectively. The Leica Q550IW image analysis 
system, a Leica DM RXA color video camera, and software based on Leica QWin Image 
Analysis were used to measure and quantify the endometrial microvessels after SMAα 
staining. First, microvascular density (MVD), the number of microvessels per high-power 
field (HPF), was determined. HPFs with a minimum of ten visible vessel lumens per HPF 
were randomly selected at ten individual spots on each endometrial slide. Thereafter, the 
number of microvessels covered with pericytes in each HPF was counted and finally summed 
for the entire endometrial slide.  
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A microvessel with >50% pericyte coverage of the perimeter was defined as a positive 
microvessel. Next, ten randomly selected CD34-stained microvessels were imaged with a 
camera on each slide using an x63 oil immersion lens.  
2.2.3 Transmission electron microscopy 
Smaller sections of the endometrial biopsies were fixed for 30 min at room temperature, and 
then for 24 h at 4˚C using 2% glutaraldehyde + 0.5% paraformaldehyde in a 0.1 M sodium 
cacodylate buffer containing 0.1 M sucrose and 3 mM CaCl2, pH 7.4. The specimens were 
then rinsed in 0.15 M cacodylate buffer and postfixed by incubating for 2 h in 2% osmium 
tetroxide in 0.07 M cacodylate buffer containing 3 mM CaCl2, after which they were 
dehydrated in an ascending series of alcohol and acetone solutions and finally embedded in 
LX-112 epoxy resin (Ladd Research Industries, Burlington, VT). The embedded tissue was 
then cut into ultrathin sections and given contrast by staining with uranyl acetate followed 
by lead citrate, after which they were examined under a Tecnai 10 (FEI, Eindhoven, 
Netherlands) transmission electron microscope at 80 kV, where thickness and endothelial 
volume density were measured. Total microvascular area was defined by the area occupied 
within the basal membrane, and luminal area as the area surrounded by endothelial cells. A 
ratio could then be calculated by dividing the luminal area by the total vascular area to obtain 
an estimate of endothelial volume density. 
Two individual observers independently performed the vascular quantifications and 
measurements in the endometrial slides after reaching agreement on defining HPFs, vascular 
lumen and positive pericyte vessels by observing sample slides together. Each observer then 
analyzed each slide at least two times.  
2.2.4 Statistics 
Data in this study are presented as median values using 95% confidence intervals (CIs). The 
Kruskal-Wallis, Mann-Whitney, and Spearman statistical tests were performed in this study 
using the Statistica software package to obtain the results. A P-value of <0.05 was considered 
to be statistically significant. 
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2.3 Study III 
2.3.1 Study design, population and data collection 
The study included all female patients with a genetically confirmed germline LS mutation 
identified between 1994 and 2013 at the department of genetics at the universities in 
Stockholm, Uppsala, Linkoping, Lund and Gothenburg. Of the 260 women who were 
identified and asked to participate, 170 agreed. Clinical data from these 170 women with 
molecularly confirmed LS were collected. Data including gynecological LS screening 
history, biopsy results (if any), genetic records, number of screening visits, results from 
screening including TVUS, endometrial biopsy (EB) and blood test for tumor marker cancer 
antigen (CA) 125, as well as prophylactic surgery including age at procedure, and the setting 
from which the screening data derived were all obtained from the medical records. All 
diagnoses in the study are based on the original pathology reports in the medical records. 
All TVUSs included assessment of endometrial thickness, uterus size, and examination of 
the ovaries (size, position, cysts, free fluid, or other sonographic abnormalities). After the 
data were collected, 160 women remained with sufficient clinical data for inclusion in the 
study.  
 
2.3.2 Statistics 
The Statistica® software package was used to perform statistical analyses in this study. A 
p-value < 0.05 was considered to be significant. All p-values are reported for all statistical 
tests in the study because of the small total patient number. The Pearson's chi-squared test, 
Fisher's exact test and Kaplan–Meier estimator were used to calculate proportional 
differences between two independent subsets of patients in the study. The Kruskal–Wallis 
test was used when it was necessary to test more than two independent samples.  
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2.4 Study IV 
2.4.1 Study design, population and data collection  
The cases in this study came from two EC cohorts. The first cohort is the Registry of 
Endometrial Cancer in Sweden (RENDOCAS) which is a hospital-based case-control study 
cohort. The patients in this cohort (n=520) underwent surgery for pathology-verified EC at 
Karolinska University Hospital in Solna, Sweden, between 2008 and 2011, regardless of 
age at diagnosis. For each patient, the following data were previously obtained: basic blood 
tests with whole genome genotyping, histological reports on tumor samples, detailed family 
history with individual pedigree based on all substantiated family data collected from the 
medical records of family members. Patients fulfilling the Amsterdam or Bethesda criteria 
had previously been screened for LS and the mutation carriers are known. Data on the 
cohort were also available for relevant environmental factors for EC (BMI, hormonal 
treatment, parity etc.), collected at the time of diagnosis. All patients included in the 
RENDOCAS cohort with no known cancer syndrome genotype were included in this study 
as cases. The remaining cases in the study derive from a cohort collected from ECs 
diagnosed throughout Sweden in postmenopausal women only, with consecutive 
enrollment beginning in1994 (n=2184) (128). The same data as in the RENDOCAS cohort 
regarding family history, genotyping and exclusion of cancer syndromes were collected.  
 
The controls were collected from the KARMA cohort described in greater detail in previous 
papers (129). In Sweden, women aged 40–74 are invited every18–24 months to participate 
in the national breast cancer screening program. Women who attended mammographic 
screening at four hospitals in Sweden with negative screening results and no other cancer 
diagnosis were invited to be included in the KARMA control cohort between January 2011 
and March 2013. All patients in the KARMA control cohort were eligible for inclusion in 
the control group in this study. 
 
2.4.2 Genotyping and quality control 
Genotyping was done on DNA extracted from peripheral blood samples of both cases and 
controls using standard procedure. The genotyping data were merged, taking TOP strand 
format into account. A total of 9080 individuals (2704 cases and 6376 controls) were 
processed for Quality Control (QC) analysis. In the first QC round (QC1), heterozygous 
haploid genotypes were excluded, as were samples with gender inconsistency and 
same position variants.  
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After QC1 474,706 SNPs and 9080 individuals (2704 cases and 6376 controls) remained in 
the data set. A second QC round (QC 2) was then performed, where SNPs with <98% call 
rate, <1% minor allele frequency (MAF) and SNPs inconsistent with the Hardy–Weinberg 
Equilibrium (HWE 0.001) in the controls were excluded, ultimately leaving 332,906 SNPs 
after QC 2. In the third and final QC round (QC 3), a multidimensional scaling (MDS) 
analysis was conducted on all remaining SNP markers to stratify the population and to 
identify ethnic outliers. These outliers were excluded from the dataset, while the remaining 
SNPs were plotted using an MDS plot in an effort to achieve maximum homogeneity 
between cases and controls. After QC 3 there were 332,906 SNPs and 9,062 individuals 
(2700 cases, 6362 controls) remaining in the dataset on which GWAS analysis could 
potentially be performed. For simplicity, we used only 1116 of the endometrial cases and 
all 5021 Karma controls to calculate the results, since this arrangement provided sufficient 
statistical power. 
 
2.4.3 Statistics 
A logistic regression model was used to examine the association between a single SNP or 
haplotype and cancer risk. Corresponding OR, standard errors, 95% confidence 
intervals and P values were calculated using PLINK v1.07. An MDS plot 
that showed P values sorted by chromosomal position was generated to provide a visual 
illustration of top association findings across the genome. A P-value of <6.0x10-9 was 
considered to meet genome-wide statistical significance of SNP according to Bonferroni-­‐
adjusted P value criteria. 
 
2.5 Ethical approvals 
Participation in the four studies was voluntary and all participants were informed about the 
voluntary nature of the studies, as well as the study aims. Informed consent was obtained 
from all participants and all data were anonymized immediately after collection. 
 
The Ethical Review Board of Karolinska Institutet South Huddinge, Sweden, granted 
permission for study I under registration no. 528/03. Study II was approved by the Ethical 
Review Board of Karolinska Institutet North under registration no. 99-299. The Stockholm 
Regional Ethics Committee (EPN) granted ethical approval for studies III and IV under 
registration no. 2010/1536-31/2.  
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3. Results 
3.1.1 Study I 
 
Figure 1: SDF-1 levels at different times of the menstrual cycle. Boxplots show medians and IQRs, as well as 
maximum and minimum values. The significant difference occurred during the mid-proliferative phase on day 5 
between HMB-E patients and controls. 
We found that the levels of SDF-1 were significantly lower overall in HMB-E patients by an 
average of 16% compared with the control group (P = 0.0001). When assessing levels during 
the different menstrual phases, a significant decrease (P = 0.013) was seen between the mid-
proliferative phase and ovulation in HMB-E patients compared with controls. The greatest 
difference in SDF-1 levels occurred when comparing the mid-proliferative phase between 
patients and controls (see figure1). 
 
VEGF-A showed a similar decreasing trend as SDF-1 in the HMB-E patients, but it was not 
statistically significant (P = 0.086), while VEGF-A levels among controls did not change 
during the different phases of the menstrual cycle (P = 0.473).  
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Figure 2A: Number of EPC-CFUs in HMB-E patients and controls. Boxplots show medians and IQRs, as well as 
maximum and minimum values. 
Figure 2B: The relationship between SDF-1 levels in blood and number of EPC-CFUs.  
X-axis = SDF-1 level (pg/ml), Y-axis = Log number of EPC-CFUs 
  
HMB-E patients also had a lower number of EPC-CFUs compared with controls (P . 0.014), 
showing a positive correlation between SDF-1 level in blood and EPC-CFUs (r = 0.428; P = 
0.047); see figures 2A and 2B.  We also found that the level of circulating endothelial cells in 
HMB-E patients was higher than in controls, although this result did not reach statistical 
significance. In contrast, the level of the EPC marker, CD34, in blood was significantly lower 
in HMB-E patients than among controls (P = 0.020).  
 
We also investigated the levels of different mature EC markers in peripheral blood and found 
that the levels of CD144 (P= 0.014), CD141 (P=0.001) and CD31 (P=0.002) were 
significantly elevated in HMB-E patients compared with controls; see figures 3A and 3B. The 
EPC marker was significantly lower in HMB-E patients compared with controls 
(P=<0.0001); see figure 3C. We also looked at homeostatic circulating molecules in 
peripheral blood and of these, HSP was found to be significantly lower in HMB-E patients 
than in controls (P = 0.009). In contrast, PAI-1 was higher in HMB-E patients (P=0.004); 
see figure 3C. 
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Figure 3A and 3B: EC surface markers for mature EC cells.  
Figure 3C: Markers for EPCs. 
Figure 4C: Circulating homeostatic regulating molecules. 
Boxplots show median values and IQRs, as well as maximum and minimum values.  
 
In all, the results in study I show differences in SDF-1 levels between HMB-E and controls, 
with significant variations during the proliferative phase. SDF-1 levels also correlate with 
number of EPC-CFUs and number of circulating EPCs in the blood, which suggests a 
possible explanation for the altered angiogenesis seen in HMB-E.   
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3.1.2 Study II 
 
Figure 1: Number of stained aSMA-covered microvessels in HMB-E patients compared with controls. The data 
are presented as means with 95% confidence interval. 
Total microvascular density did not differ between HMB-E patients and controls, with a 
median of 19.5 microvessels/HPF (standard deviation (SD) 6.0; 95% CI) in HMB-E 
patients compared with 16.0 microvessels/HPF (SD 2.5; 95% CI) in controls, but the 
number of SMAα-positive microvessels in the proliferative phase was significantly 
(P=0.005) lower in HMB-E patients than in controls (27 (18-34) 95% CI for patients vs 42 
(35-49) 95% CI for controls); see figure 1. 
 
The number of microvessels that expressed VEGF-A was significantly higher in HMB-E 
patients over the entire menstrual cycle with a median of 17 (16-22) 95% CI for patients 
and 10 (9-15) 95% CI for controls. The measured luminal perimeter of the endometrial 
microvessels also showed a significant change during the secretory phase, with a median 
increase of 9.3 µm ((6.1-14.9) 95% CI) in HMB-E patients compared with 3.6 µm ((1.3-7.2 
µm) 95% CI) in controls (p=0.0007). 
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Figure 2: Correlation between number of pericyte-covered microvessels and number of VEGF-A positive 
vessels in the proliferative phase of HMB-E patients and controls.  
 
When assessing pericyte coverage of aSMA-positive microvessels within the control group, 
a significant decrease in coverage was seen during the secretory phase (P=0.04) compared 
with the proliferative phase, while among HMB-E patients coverage did not differ between 
menstrual phases. When correlating coverage of aSMA microvessels with expression of 
VEGF-A in both controls and HMB-E patients, a significant negative correlation was 
observed between expression of VEGF-A and pericyte coverage (r=0.8; P=0.04); see figure 
2.  
 
The endothelial density as measured by electron microscopy revealed that endothelial cells 
accounted for a significantly higher percentage of total vessel area compared with controls 
(median 77.4 % (70.4-81.8) 95% CI vs 53.3 % (49.6-58.4) 95% CI, P<0.0001). No 
morphological defects were seen within the endothelial cells or the pericytes, nor was any 
defect in cell adhesion or cell contact evident.  
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3.1.3 Study III 
 
Figure 1: Flow chart for female LS carriers recruited to the study. 
Of the 170 women contacted for the study, 160 had sufficient clinical data for inclusion. 
Among these, 79 had MLH1, 51 MSH2, 25 MSH6, and 5 PMS2 mutations.  
Further analysis showed that 43 women had undergone hysterectomy with or without 
bilateral salpingo-oophorectomy prior to a diagnosis of LS; consequently, these cases could 
not be used to assess the effectiveness of the screening program for gynecological cancer in 
LS carriers. Interestingly, the indication for surgery was EC in 35 of these cases (81%) and 
ovarian cancer (OC) in 3 cases (7 %), while the remaining 5 cases were for benign indications 
(11%). Another subset of women (n=26) who were known LS carriers, but too young to have 
started the cancer screening program, could not be included to assess the effectiveness of the 
screening program. Additionally, 3 patients chose not to attend the screening program, and in 
two cases the physician opted not to screen at all. In all, of 160 patients, only 86 patients 
remained who were known LS carriers and had attended one or more gynecological screening 
visit.  
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In this group of 86 women, 41 (47.7%) eventually underwent prophylactic hysterectomy 
and/or bilateral salpingo-oophorectomy. Two patients from the prophylactic surgery group 
(4.9%) were postoperatively diagnosed with EC and two (4.9%) with atypical hyperplasia of 
the uterus. The remaining 45 (52.3%) women instead regularly attended gynecological 
surveillance with no decision to have prophylactic surgery. The total incidence of 
gynecological cancer in this group was 20% EC and 4% OC. Five patients had EC and two 
had complex hyperplasia with atypia, all asymptomatic and detected by EB during screening 
visits. Four additional cases were detected because of interval bleeding between visits. Two 
cases of OC were detected by TVUS in patients with ovarian cysts under surveillance. The 
youngest woman with EC was diagnosed at age 35, before she was aware of her diagnosis of 
LS. 
 
Figure 2: Proportion of cancer-free women from time of LS diagnosis to time of gynecological cancer diagnosis. 
Red line = prophylactic surgery group. Blue line = surveillance group  
The incidence of gynecological cancer showed a clear declining trend in the group of women 
who opted for prophylactic surgery, although this trend did not reach statistical significance, 
possibly because of the low total number of participants in the two groups; see figure 2. 
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3.1.4 Study IV 
Using a 25 base-pair frame for the SNP analysis, we identified five distinct haplotypes in the 
EC group, none of which had been described earlier in the literature, and which were 
associated with an increased risk of endometrial, cancer compared with controls.  These 
haplotypes were found on chromosomes 2, 10, 13, 15 and 20, and contained between 7 and 
17 SNPs, with lengths ranging from 1445 to 89,722 base pairs; see table 1 and figure 1. 
Chromosome	   P-­‐value	   Odds	  ratio	  EC	  (OR)	   Frequency	   Bp-­‐lenght	  
Chr2	   1.53E-­‐10	   2.15	   0.0301	   1445	  
Chr10	  	   1.32E-­‐9	   3.05	   0.0158	   89722	  
Chr13	   3.45E-­‐9	   2.19	   0.0278	   61989	  
Chr15	   3.27E-­‐9	   2.17	   0.0233	   13952	  
Chr20	   5.0E-­‐10	   1.97	   0.0369	   40517	  
Table 1: The five risk haplotypes found in the EC population and their p-values (significance= < 6x10-9).  
OR = Odds ratio for EC compared to the control group.  
Frequency = Frequency of occurrence of the haplotype in the study group of EC patients as a whole.  
Bp-length = Basepair length  
 
 
 
The haplotype on chromosome 2 is located in the ITGA6 (integrin subunit alpha 6) gene. All 
SNPs in the haplotype occur in intron sequences of the gene.  The ITGA6 protein is highly 
expressed in normal endometrial tissue, especially in endometrial glandular cells. The subunit 
forms a heterodimer with a beta chain and resides in the cell membrane where it interacts 
with the ECM.  ITGA6 expression is known to be a favorable prognostic marker in renal 
cancer (p<0.001) and an unfavorable marker in head and neck cancer (p<0.001). ITGA6 has 
not been shown to be of any prognostic value in cancers of the female reproductive tract, 
although in vitro studies of overexpression have shown a general link to an aggressive 
metastatic phenotype (130). Other in vitro studies have shown a link between ITGA6 
expression and higher invasiveness in gallbladder cancer, and that blocking ITGA6 
suppresses tumor growth and angiogenesis (74, 131). 
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Figure 1: The rs numbers and the SNP order in each of the five risk haplotypes 
The haplotype found on chromosome 10 is located in the TTC40 gene. This gene codes for 
the CFAP46 protein, which is expressed in benign fallopian tube tissue, but found in EC 
tissue as well. Three SNPs in this haplotype (rs 2254419, rs4880433, rs10870341) are located 
in the coding sequence for the TTC40 gene, where the minor allele  leads to missense 
mutation variants (rs 2254419  S/G, rs4880433 A/T , rs10870341 C/R),  but with no known 
evident effect on protein function. Expression of CFAP46 has no evident prognostic value for 
any cancer. Interestingly, in a Japanese population the SNP rs2254419 (G) missense variant 
has been associated with obesity, a well-known major risk factor for developing EC (132).  
The haplotype on chromosome 13 spans one gene (TUBA3C) and two pseudogenes 
(CENPIP1, SMPD4P2), including the intergenic regions. All the SNPs reside in the intron 
sequence of the genes. Normally, TUBA3C is found only in testicular tissue, but in cancer it 
may be expressed in several tissues, especially in the female genital tract and breast tissue. 
There is no evidence that the protein is associated with any prognostic value for any cancer.  
 
 
	  
Chr2	   	  	   Chr10	   	  	   Chr13	   	  	   Chr15	   	  	   Chr	  20	   	  	  
SNPs	   H	   SNPs	  
	  
H	   SNPs	   H	   SNPs	   H	   SNPs	   H	  
rs12053442	   G	   rs913191	   A	   rs17090505	   A	   rs12902616	   A	   rs4813847	   A	  
rs3108780	   A	   rs2767438	   G	   rs1974048	   C	   rs11853552	   G	   rs1012891	   C	  
rs6757785	   A	   rs2254419	   T	   rs7320243	   G	   rs11857190	   A	   rs6055457	   A	  
rs76264695	   G	   rs4880433	   C	   rs9319225	   T	   rs11857997	   T	   rs6039000	   T	  
rs35265291	   C	   rs10870341	   A	   rs4770842	   G	   rs8031842	   G	   rs2205782	   T	  
rs3115745	   T	   rs7095353	   A	   rs61742516	   A	   rs1554865	   T	   rs67898032	   G	  
rs36055280	   G	   rs7907613	   T	   rs518637	   C	   rs1881538	   A	   rs6133527	   C	  
	   	   	   	  
rs9511884	   A	   rs12914734	   T	   rs2294248	   G	  
	   	   	   	  
rs2006655	   C	   rs11638007	   A	   rs2205783	   G	  
	   	   	   	  
rs2774494	   T	   rs11632715	   A	   rs6039005	   G	  
	   	   	   	  
rs9507572	   A	   rs1534594	   T	   rs6055475	   C	  
	   	   	   	   	   	  
rs12594148	   T	  
	   	  
	   	   	   	   	   	  
rs12592288	   G	  
	   	  
	   	   	   	   	   	  
rs3812934	   C	  
	   	  
	   	   	   	   	   	  
rs1406389	   T	  
	   	  
	   	   	   	   	   	  
rs2293581	   G	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The haplotype on chromosome 15 resides in a regulatory region with binding sites for several 
transcription factors. Of these, expression of the E2F3 transcription factor is known to be a 
favorable prognostic finding in OC. However, recent studies have shown that the Mir-152 
microRNA, which usually acts as a tumor suppressor, is often methylated and silenced in 
ECs. One of the main targets of Mir-152 is E2F3, which may indicate that this transcription 
factor plays a role in EC that is not yet fully understood (133, 134). Another factor, PITX1, 
binds to the same region and is usually overexpressed in cervical cancer, but has no 
demonstrated prognostic value in any disease so far. However, PITX1 has been shown to act 
as a target for ERa in ER-positive breast cancer, with up-regulation of both PITX1 and its 
target genes, although other ER-dependent cancers in other tissues have not been studied in 
this regard thus far (135). 
ZSCAN16 is another transcription factor that binds to the same region and is associated with 
a favorable prognosis in ovarian and cervical cancer. One study has shown a significant 
alteration in the epigenetics of the regulatory region for the ZSCAN16 gene on chromosome 
6 in ER-positive breast cancer with subsequent overexpression of the protein in those cancers. 
ZSCAN16 expression in other ER-dependent tumors is not known (136). None of the 
transcription factors binding to the region where this haplotype is located are currently known 
to be altered or to have a prognostic value for EC. 
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4. Discussion 
4.1.1 Study I 
This study demonstrated altered levels of SDF-1 in HMB-E patients compared with healthy 
women. The underlying mechanism is unknown, nor is it known whether the systemic 
circulation or the local circulation within the endometrium is the source of the SDF-1. 
Because SDF-1 levels vary cyclically with the menstrual cycle in healthy women, and the 
endometrium is known to be the site of angiogenesis during the proliferative phase, it 
suggests that the main source of peaking SDF-1 during the proliferative phase is the 
endometrial response to stimulation by estradiol and progesterone.  
A previous but similar study undertaken on endometrium and blood from healthy women also 
showed cyclical variation of SDF-1 levels with the menstrual cycle, which correlated 
negatively with the number of EPC-CFUs that could be formed in vitro (137). The study 
concluded that during the proliferative phase, healthy endometrium appears to produce SDF-
1 to recruit EPCs to the growing vessels, while incorporation of EPCs into the vessels results 
in a negative feedback loop on SDF-1 production. This conclusion is consistent with the 
findings of this study as well, and may serve as a possible explanation for the high blood loss 
in HMB-E patients should such recruitment malfunction, thereby rendering leaky vessels 
because of fewer ECs.  
 
However, studies conducted using different methodology showed contradictory results. A 
study by Laird et al. that measured mRNA expression in endometrial biopsies from healthy 
fertile women during different phases of the menstrual cycle did not detect any significant 
changes in SDF-1 expression, but did find a significant change in CXCR4 mRNA expression 
with substantially higher levels of expression localized to the vascular walls during the early 
proliferative phase compared with all other phases in the cycle (138). Although no change in 
SDF-1 was seen, the CXCR4 mrRNA expression in the proliferative phase seen in this study 
is actually consistent with our own study, which found that SDF-1 signaling is likely to be 
most active during this phase. The lack of a SDF-1 mRNA peak in the biopsies may be due to 
different study methodology since Laird’s group extracted mRNA from solid tissue, while 
our study extracted it from blood; this may indicate that most of the SDF-1 in the 
endometrium is in soluble form. However, these findings beg the question of whether SDF-1 
actually originates in the endometrium or from peripheral tissue. 
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This study also showed a significant decrease in the number of EPC-CFUs among HMB-E 
patients with a positive correlation between SDF-1 levels and number of EPC-CFUs; 
moreover, the number of circulating EPCs was significantly lower in patients than in controls. 
These findings are also in line with the previous study (78), which suggested that SDF-1 is 
important for recruitment of EPCs from the bloodstream to endometrial vessel walls. The 
question is how lack of recruitment could affect angiogenesis and the integrity of the 
endometrial vessels, since other known angiogenic pathways may possibly provide sufficient 
compensation. 
 
In a mouse model study using DNA marked cells originating from hematopoietic tissues to 
create granulation tissue, the number of endothelial cells of hematopoietic origin in the 
granulation tissue was compared with other mature tissues and significant differences were 
found. In the granulation tissue, endothelial cells of hematopoietic origin accounted for 8.3-
11.2%, while the percentage was much lower in other tissues, 0.2-1.4 % (139). This indicates 
that incorporation of circulating EPCs is an important mechanism for acquiring endothelial 
cells in adult tissues, where de novo angiogenesis from existing mature vessels takes place. 
This may be even more important in the endometrium since vessel sprouting does not seem to 
be the main mechanism of new vessel formation (19). EPCs have also been shown to express 
both estrogen receptors alpha and beta (140), making them sensitive to estrogen stimulation, 
which in vitro has been shown to increase EPC proliferation (141). This could also explain 
why recruitment of EPCs may be an extremely important source of endothelial cells, 
especially in the endometrium. 
 
Several studies have reported that the ability to recruit EPCs during angiogenesis and 
vascular injury is beneficial for vascular integrity in patients with or at risk of cardiovascular 
disease (142-144), including evidence that recruitment protects the vascular wall from further 
injury. The important role of EPCs in neovascularization of ischemic tissues has also been 
shown by several studies (145), further suggesting the importance of the endometrium to 
neovascularization since local hypoxia is critical to the shedding process. A recent study has 
described the mechanism by which SDF-1 release into the bloodstream is activated by HIF-a 
in hypoxic tissue, and how SDF-1 both recruits EPCs from the bone marrow and attracts 
these cells to ischemic tissue through simultaneous upregulation of E-selectin on existing ECs 
(74). These findings provide a key as to how hypoxia, SDF-1 and EPCs interrelate in the 
neovascularization process; our study findings also fit this paradigm. 
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4.1.2 Study II 
The main finding of this study was the significantly lower pericyte coverage of microvessels 
during the proliferative phase in HMB-E patients compared with controls; moreover, pericyte 
coverage decreased during the secretory phase among controls, while coverage remained 
stable throughout the phases of the menstrual cycle in HMB-E patients. This finding supports 
the hypothesis that HMB-E primarily results from dysregulated angiogenesis.  
 
As previously mentioned, the pericyte is important for EC function and stability. This study 
does not answer the question of whether dysregulation stems from the pericyte or from 
inability of ECs to recruit them properly. One finding that suggests the latter explanation is 
the negative correlation between VEGF-A levels and pericyte coverage, which might indicate 
that the strong VEGF-A signal from endothelial cells primarily inhibits pericyte adherence 
during neovascularization in the proliferative phase, ultimately leaving behind immature 
vessels that are prone to leakage. VEGF-A and its binding to the VEGF-R2 receptor on 
mesenchymal cells have been shown to inhibit the PDGFR-B receptor on the same cells, 
thereby preventing proliferation and recruitment of these cells into newly formed EC tubes 
(146). The same study also tested pericyte coverage of microvessels in mice treated with 
PDGF or VEGF-A alone or in combination. Monotreatment with PDGF clearly led to robust 
recruitment of pericytes and formation of new vessels, while the combination of PDGF and 
VEGF-A resulted in inhibition of vascular formation, suggesting an antagonistic relationship 
between the two factors. Both this study and prior studies have shown significant 
overexpression of VEGF-A throughout the menstrual cycle in HMB-E patients (52, 147, 
148). This finding, along with the inhibitory effect VEGF-A has on pericytes, may explain 
the disruption of vascular morphology among HMB-E patients in this study.     
 
Similar to the findings in the first study on SDF-1, pericyte coverage was cyclical in healthy 
controls, with highest coverage seen during the proliferative phase and a decrease during the 
secretory phase, while coverage in HMB-E patients remained unchanged throughout the 
menstrual cycle. The reason why the endometrium of HMB-E patients lacks such a response 
in the proliferative phase is unclear. Endometrial growth is controlled by estrogen and 
progesterone, where estrogen levels are highest during the proliferative phase; however, 
studies have shown that estrogen may be both pro or anti-angiogenic under different 
circumstances (12).  
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What is known from ovariectomized mouse models is that single treatment with estradiol 
leads to angiogenesis in the endometrium through mediation of VEGF-A, since blocking of 
VEGF-A results in complete absence of new vessels with estradiol treatment (149); however, 
these vessels failed to show recruitment of pericytes. In contrast, treatment with progesterone 
had a strong positive effect on pericyte proliferation and coverage of vessels, which remained 
unaltered regardless of whether or not estrogen was used for pre-treatment (150). Logically, 
this would suggest that the highest coverage would be expected during the secretory phase 
rather than the proliferative phase, as in the case of our study. Abberton et al. studied 
coverage of aSMA cells around spiral arterioles and showed higher coverage during the 
secretory phase (151, 152). The same group conducted a comparative study between HMB-E 
patients and controls regarding aSMA expression in spiral arterioles and found no significant 
differences (153). It should be noted that these studies examined large vessel maturation, 
rather than microvasculature, as in our study. It may be possible that the need for pericyte 
coverage in the microvasculature changes as the larger vessels mature and become contractile 
later in the cycle, when they can start to regulate peripheral blood flow more efficiently, 
ultimately rendering pericyte coverage in the capillaries unnecessary during the secretory 
phase. Further studies of HMB-E patients and healthy controls comparing aSMA/pericyte 
coverage between arterioles and microvessels would be of interest.  
 
Our study also identified morphological changes in microvessel lumens among HMB-E 
patients that were not present in controls, including an increase in endothelial cell area of 
vessels and an increase in vessel perimeters. As previously mentioned, earlier studies have 
shown that HMB-E vessels lack essential vasoconstrictors such as ET-1 and PGF, which 
would affect vascular tone and vessel perimeter. Lack of aSMA could also contribute to these 
morphological changes since involved vessels lose the ability to contract. This inability to 
contract results in a larger vessel perimeter, which could also help explain increased leakage 
in vessels.  
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4.1.3 Study III 
To our knowledge, this is the first study that attempted to determine the effectiveness of 
gynecological surveillance in Sweden. We found that 15% of women in the surveillance 
group developed cancer over the course of the surveillance period. This may appear to be an 
unexpectedly low percentage given that the lifetime risk of EC in LS carriers is 
approximately 50%. The explanation may lie in the relatively short follow-up period for each 
case and the high frequency of prophylactic hysterectomies (48%) in the cohort.   
 
The overall question is how screening for gynecological cancers among LS carriers affects 
morbidity and mortality in the group since it is known that EC usually gives rise to early 
symptoms like occult vaginal bleeding and is therefore diagnosed at an early stage with an 
excellent cure rate by surgery alone (154). It should be noted, however, that this is true for 
FIGO stage I EC that accounts for approximately 80% of all cases with a five-year survival 
rate of 95%. For FIGO II-V, which account for the remaining 20%, the long-term prognosis 
is much worse with a five-year survival rate between 25-75% 
(https://www.cancercentrum.se/globalassets/cancerdiagnoser/gynekologi/kvalitetsregister/nati
onell-kvalitetsrapport-gynekologisk-cancer-2017.pdf), for which reason screening could be 
especially beneficial for such LS patients.  
 
Our study identified four cases of FIGO stage I-II EC because of bleeding between checkups, 
which was not different in stage from the other EC cases detected during checkups. This 
could indicate that early detection is not significantly improved by the checkups themselves 
but rather that awareness of increased EC risk in this subset of patients who bleed may be the 
most important factor for prevention of patient and/or doctor delay for finding cancer at an 
earlier stage. A large national study by De Jong et al. that compared mortality rates for 
different cancers in 140 Lynch families in the Netherlands before and after introduction of the 
national screening program in 1987 did not detect any significant decrease in EC mortality 
(155). This could be explained by the relatively low mortality rate associated with EC overall, 
but could also indicate that the gynecological screening methods were not effective. A study 
in Finland that followed 175 known female mutation carriers showed promising results for 
the effectiveness of gynecological surveillance by detecting 14 cases of EC and 14 cases of 
premalignant complex hyperplasia. All of the women detected through the surveillance 
program survived their EC, compared with a group of 83 women with symptomatic EC, 6 of 
whom died from the disease, although this difference does not reach statistical significance.  
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More importantly, this study shows that screening methodology is crucial in order for 
screening checkups to detect EC or hyperplasia, since in the relevant study EB detected all 
cases of hyperplasia and 8 ECs, while ultrasound found only 4 ECs and missed all cases of 
hyperplasia (156).  
 
These findings are consistent with our own results since in our study the 5 cases of EC and 
complex hyperplasia found in asymptomatic women were diagnosed through EB, while 
TVUS missed all of these cases. Of the four cases that presented with symptoms between 
visits, EB detected EC in all cases while TVUS only saw thickening of the endometrium in 
two cases. This indicates that in order for EC surveillance to be effective, EB must be used. 
Other studies have reported a paucity of findings from TVUS screening for EC detection, 
while yet others have concluded that annual screening is sufficient, and that EB is only 
indicated when symptoms of occult bleeding occur (157). 
 
The most effective intervention to prevent gynecological cancer in LS patients is prophylactic 
hysterectomy with or without bilateral oophorectomy, which reduces risk of both EC and OC. 
Our study uncovered four additional cases of EC in patients who had already undergone 
prophylactic surgery. The optimal time to carry out this procedure is still debatable; to date, 
no study has shown a decrease in long-term mortality among prophylactically operated 
patients. The current recommendation is to opt for surgery when having children is no longer 
an issue, although this also gives rise to other questions concerning surgical risk and early 
menopause, which may have negative long-term effects on health and quality of life.  
 
Our study also investigated whether there were any screening procedure differences between 
university, county and private clinics. No significant differences were found, although 
regarding age distribution, private clinics demonstrated a trend to continue screening into 
older age groups before referral for prophylactic surgery, compared with university and 
county hospitals, which tended to refer patients for surgery earlier. This may reflect either a 
patient or care provider bias. It may be in the interest of private care providers to keep 
patients under surveillance as long as possible for economic reasons, but alternatively the 
explanation may be that patients who do not want to undergo surgery actively avoid 
surveillance at hospital clinics.  
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One limitation of this study is its retrospective design, which may lead to selection bias. In 
this regard, selection bias may be detrimental to the conclusions of the study since awareness 
about LS and the risk of developing cancer may be the most important single factor for 
reducing mortality in this group, so if this subgroup of LS-aware carriers is more likely to 
participate in this study there could be substantial confounding of results. We cannot check 
for this since we do not have access to the medical records of non-participants. The strength 
of the study design, however, is that it provides a good representation of the effectiveness of 
the surveillance program in Sweden without the risk for recall or ascertainment bias, which 
would be the case if the study had a prospective design.  
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4.1.4 Study IV 
Our results demonstrate five haplotypes that are significantly more abundant in a Swedish 
cohort of EC patients compared with controls. Nevertheless, the frequency of these 
haplotypes is fairly low among all cancer patients; the most frequent haplotype located on 
chromosome 20 is present in 3.69% of all ECs. The odds ratio for all chromosomes is also 
relatively low; the haplotype on chromosome 10 is associated with the highest OR of 3.05. 
Overall, this indicates that the haplotypes that were discovered are insufficient to account for 
development of cancer in individual patients, but may explain the increased occurrence of EC 
in a larger homogeneous group of people. This idea is also consistent with the location of the 
haplotypes in the genome, since no individual SNP in these haplotypes leads to deleterious 
mutation of any protein, as might be expected if the SNP haplotype itself were the direct 
cause of disease. Instead, as expected these SNPs are either located in noncoding regions or 
intergenic regions of the genome. These SNPs are mostly found in intron sequences or lead to 
missense variants, with no apparent effect on protein function. 
Interestingly, these genes and the transcription factor binding regions in which the five 
described haplotypes are found have been associated with estrogen-dependent cancers, 
especially breast cancer. Endometrioid EC is also estrogen-dependent, and the environmental 
factors associated with this disease are strongly linked to estrogen excess (158-160), which 
could explain the increased susceptibility for EC among these haplotypes. Neither potential 
estrogen excess nor other environmental risk factors for EC have been investigated among 
the patients and controls in this particular study, which is a weakness of the study design.  
These five haplotypes may also affect the epigenetic structure of the genome. Studies 
involving other types of cancer have shown that different alleles affect methylation of DNA 
differently, and thereby also transcription of genes. One striking example is methylation of 
the MLH1 promoter in CRC (161), where different MLH1 alleles render the DNA more or 
less susceptible to methylation. Other studies have shown a similar pattern in other loci 
associated with CRC within non-coding regions of the genome (162, 163). Another possible 
explanation for increased susceptibility to EC for these haplotype carriers could be linkage 
disequilibrium with adjacent genes on the chromosome that may be more closely related to 
EC pathology.  
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The haplotype on chromosome 20 is located between the PLCB1 and HAO1 genes. Neither 
of them is known to be linked to cancer pathogenesis. The haplotype on chromosome 15 is 
located between GERM1 on one side and ARHGAP11A and SCG5 on the other. GERM1 is 
upregulated in endometriosis and has been linked to EC (164, 165). Meanwhile, SCG5 
polymorphism has been linked to an increased risk of CRC, but no studies of EC have been 
conducted in relation to this locus (166). 
The chromosome 13 haplotype has no other transcript genes in close proximity. The 
haplotype on chromosome 10 lies close to the INPP5A gene, the presence of which is an 
unfavorable prognostic factor in breast cancer. This gene is usually overexpressed in all 
cancers of epithelial origin, including cancers of the female reproductive tract. INPP5A 
overexpression has been shown in vitro to inhibit cell proliferation and to increase apoptosis 
in cervical cancer cells, suggesting a tumor-suppressing effect in some tissues (167).  
Finally, the haplotype on chromosome 2 is located near the PDK1 gene. The presence of this 
gene has an unfavorable prognosis in cervical cancer. PDK1 is involved in the akt-mTOR 
pathway in the cell, which stimulates cell survival, and one study showed that altered 
phosphorylation of PDK1 in EC cell lines influenced cancer cell viability in vitro (168). 
The strategy of using haplotype analyses is based on the assumption that Sweden has a fairly 
homogeneous population. A prior study using a similar approach identified seven novel risk 
loci for cancer in a Swedish population, although those risk loci were not associated with any 
specific type of cancer (169). It has long been known that EC differs among various 
ethnicities regarding clinical outcome; it has been suggested that this is due to a combination 
of both environmental and genetic factors (170, 171). A recent study compared the protein 
profiles of ECs among people of different ethnicities using the human genome atlas and 
found clear differences in molecular profile between African American, Caucasian, and 
Asian women (172). Although this study cannot answer the question of whether tumors are 
due to environmentally induced mutations or genomic susceptibility, it does indicate that 
tumor development varies based on inherited genomic differences, where inherited 
haplotypes may be one of many important factors.  
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5. General conclusions 
Endometrial angiogenesis 
• Study I confirmed a cyclical difference in SDF-1 levels between the proliferative and 
secretory phases of the menstrual cycle in non-HMB-E subjects. 
• Study II study showed a cyclical difference in pericyte coverage of microvessels in 
the endometrium between the proliferative and secretory phases in non-HMB-E 
subjects. 
• A cyclical pattern of SDF-1 levels and pericyte coverage was absent in HMB-E 
patients in whom both were significantly lower during the proliferative phase. 
• The number of EPC-CFUs was lower in HMB-E patients than in controls, suggesting 
that EPC incorporation during physiological angiogenesis of endometrial vessels 
plays an important role. 
• The number of EPC-CFUs correlated positively with SDF-1 levels, which indicates 
that the SDF-1/CXCR4 axis is responsible for recruitment of EPC-CFUs into the 
bloodstream, which is in line with previous literature. 
• Pericyte coverage of microvessels correlated negatively with VEGF-A levels in the 
endometrial vessels, indicating that overexpression of VEGF-A has a negative effect 
on microvascular maturation. 
Hereditary factors in the endometrium 
• Study III showed a high percentage of prophylactic hysterectomy (52.3%) after 
childbearing age among women who were known LS carriers. 
• A total of 5 ECs and 2 endometrial hyperplasias were found during surveillance visits. 
All these cases were diagnosed through endometrial biopsy; 4 ECs were found 
between visits due to symptoms.  
• All ECs found in the study were in FIGO stage I-II. Whether this favorable outcome 
is due to the surveillance program or the mere knowledge of the increased risk of EC 
is unknown. 
• Study III could not determine whether gynecological surveillance itself reduces 
morbidity or mortality in female LS carriers. 
• Study IV found five haplotypes that were significantly overexpressed in women with 
a family history of EC, but who had no cancer syndrome themselves. 
• All five haplotypes were found in genes or chromosomal regions with no apparent 
effect on risk of EC; the reason for overexpression is not yet known. 
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 6. Future perspectives 
 
6.1 Novel HMB-E treatments 
Current HMB-E treatments effectively decrease blood loss, but unfortunately, they all have a 
contraceptive effect, which makes them unsuitable for women with HMB-E who wish to 
become pregnant. Moreover, all current HMB-E treatments address the symptoms, without 
affecting the underlying pathogenesis. This research suggests that HMB-E patients have both 
altered EPC recruitment to endometrial vessels during physiological angiogenesis and a 
change in endometrial vascular maturation, as indicated by low pericyte coverage. 
  
Based on this research, a future goal may be to search for novel drugs that could either 
stimulate EPC recruitment to the endometrium or pericyte recruitment to immature vessels. 
Further studies are needed to elucidate whether HMB-E is primarily due to defective 
angiogenesis or failed vessel maturation, or possibly both simultaneously. A topic of interest 
for future study is to elucidate whether administration of a PDGF-b agonist or a VEGF-A 
inhibitor to HMB-E patients in vivo shortly before or during menstruation could enhance 
vascular maturation and reverse the symptoms. The difficulty with such a study would relate 
to mode of administration. Preferably, the substance would be administered locally into the 
endometrium, but such an approach would require hospital resources. On the other hand, oral 
administration would be associated with a risk of systemic side effects. 
 
A third approach is to increase incorporation of EPCs into the endothelium of vascular walls 
and thereby possibly improve the angiogenic process, but first other issues must be addressed. 
Our study investigated systemic SDF-1 levels in the bloodstream, a substance that 
purportedly exerts its main effect by causing EPC detachment from the bone marrow. Local 
expression of is also needed to attract EPCs into the growing endometrial vessels. SDF-1 
production could be stimulated by inducing local hypoxemia, but this approach would 
increase VEGF-A levels and thereby have a negative impact on vascular maturation. A 
different strategy could involve in vitro cultivation of EPCs which could be readministered to 
the patient during menstruation in an effort to reduce bleeding. However, although this 
strategy would hardly be considered cost-effective as clinical treatment, it could reveal the 
potential importance of EPCs in the pathogenesis of HMB-E. 
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6.2 Improved LS surveillance programs 
As genetic analysis improves, a greater number of patients will be diagnosed with cancer 
syndrome requiring accurate and cost-effective medical surveillance. Our study found no 
obvious benefit regarding tumor stage or long-term survival among women with known LS 
who were diagnosed with EC as a result of surveillance or symptoms between visits. Instead, 
the most important factor appears to be awareness of LS, but that may be reinforced by the 
surveillance program. A possible future study focused on tumor stage and long-term outcome  
could compare one group of LS patients who attend annual gynecological screening with a 
similar group that only receives yearly EC risk reminders from their clinical geneticist.   
Another study, previously discussed in the literature, suggests combining annual 
colonoscopies with simultaneous endometrial biopsies. Such an approach could make 
surveillance more efficient by reducing the need for separate procedures, thereby saving both 
time and resources. 
The time at which to recommend gynecological prophylactic surgery is still under debate 
since the risk of cancer must be weighed against surgical risks and the effects of early 
menopause induced by bilateral oophorectomy. Because penetrance of EC varies depending 
on which of the four genes is affected, a general surveillance program must be designed to 
take this into account and the recommended time of prophylactic surgery should be based on 
this information. The recommendation for MLH1 and MSH 2 mutation carriers should 
probably be to have prophylactic surgery between age 40-50. MSH6 carriers could remain 
under surveillance without risk for a longer time and could possibly refrain from prophylactic 
surgery before menopause since EC would not be expected until late in life, provided that 
they do not have a family history of early EC. 
6.3 Improved EC-risk assessment 
New genetic variants are constantly being identified and an increasing number are linked to a 
higher risk of certain diseases, including EC. Usually such genetic risk factors interact with 
environmental risk factors, which makes certain populations more likely to develop certain 
diseases. Regarding EC, for which we have already identified several environmental risk 
factors, information concerning the genetic make-up of individual patients could help to 
better predict their risk of developing disease, given knowledge of environmental hazards.  
 
  55 
However, more studies are needed to explore the relationship between known polymorphisms 
and environmental risk factors to address the possible risk of confounding that has not 
previously been elucidated. For example, should it be the case that the increase in relative risk 
for EC in certain populations can be more or less fully explained through inheritance of BMI, 
then additional genetic profiling would not provide useful information to the clinician.     
6.4 The relationship between HMB-E and EC 
The studies in this thesis have focused on angiogenic and hereditary risk factors for HMB-E 
and EC separately. As the thesis explains, known angiogenic factors are involved in 
development of EC and there are indications that hereditary factors are involved in HMB-E. 
Surprisingly, to date no studies have addressed HMB-E as a possible independent risk factor 
for EC, given that normal menstrual physiology is so tightly intertwined with the physiology 
of angiogenesis. It would not be difficult to imagine that the dysregulation of angiogenesis 
seen in HMB-E could act as a breeding ground for mutations and thereby for uncontrolled 
cell proliferation at a future stage. Such studies would be even more revealing in populations 
with a high incidence of EC among premenopausal women, for example in LS carriers. Even 
if the LS mutation explains the increase in cancer risk, could that risk be reduced through 
control of endometrial angiogenesis?  Furthermore, would it be possible to predict and 
control HMB-E and angiogenesis if the underlying hereditary factors are known? 
The first future task would be to design a clinical case-control study to compare the incidence 
of EC in women with confirmed HMB-E with a control group, and to check for confounding 
risk factors during selection. A second study could be to look at VEGF-A expression, as well 
as SDF-1 and EPC levels in peripheral blood in HMB-E patients and attempt to correlate 
those levels with risk of developing EC later in life. Conversely, it would be interesting to 
compare EC cases that have a known hereditary component with ECs of other origin 
regarding menstrual history, to assess the rate of HMB-E in these EC subsets, which would 
also provide greater insight into the etiology of HMB-E.     
In conclusion, HMB-E and EC are two separate diagnoses that both share some risks and 
pathophysiological abnormalities. The future could possibly reveal that in certain cases, 
HMB-E should be regarded as pre-stage EC, and thereby highlight the importance of accurate 
diagnosis and appropriate treatment of HMB-E.  
 
 
 56 
 
  57 
7. ACKNOWLEDGEMENTS 
I would first like to thank my main supervisor Miriam Mints for taking me under your wing 
and for your professionalism and guidance throughout my Ph.D. studies. This thesis would 
not have been possible without your ideas, knowledge, encouragement, and especially, least 
your patience with me as your Ph.D. student. I know that my own level of ambition has 
oscillated over the years in this project, but you have always kept me on track, moving 
forward, and for that I cannot thank you enough.  
Many thanks to my co-supervisor and chairman of the department of medicine at Solna, 
Kristina Broliden for imparting your amazing knowledge in the fields of angiogenesis and 
inflammation in particular, but also for guiding me toward the Department of Internal 
Medicine in Solna, where you introduced me to your wonderful research group, with whom I 
have had fantastic exchanges during journal clubs, seminars and courses at the department.   
The greatest thank you and respect goes to senior professor Jan Palmblad, whose 
phenomenal knowledge has impressed me since we first met. You have become a person to 
whom I look up both as a clinician and a scientist. Without your ideas, the first two studies in 
this project would never have come about.  
A special thank you goes to senior professor Annika Lindblom at the Clinical Genetics 
Department for your great wealth of knowledge in the field of genetics, which I can in no 
way match, but you always took the time to explain the necessary mechanisms to me when 
they were difficult to understand. And without you, the last two studies would not have been 
possible. 
A great thank you is goes out to MD Ph.D Emma Tham at the Clinical Genetics Department 
– you have always been so friendly and helped to guide me through many difficult aspects in 
the field of genetics in the two last studies. I have really appreciated your cooperation. 
A person I cannot thank enough is the administrator at MedS, Lillemor Melander, for 
managing the administrative side of my journey through KI and my Ph.D, which is a great 
achievement considering that lack of enthusiasm for administration. Thank you very much!   
I would like to thank Gerasimos Tzortzatos for your partnership during the work on the 
third study. The subject was completely new for both of us, but somehow we found a way to 
overcome the obstacles together. It is always fun to work and talk with you. 
A warm thank you goes to Elzafir Elsheikh with whom who I worked on the first study and 
who introduced me to many key research concepts in general. Your knowledge in the fields 
of cell biology and cell signaling is impressive. 
A big thank you goes to Inger Vedin at the CIM laboratory at KI Huddinge for your amazing 
knowledge within the field of antibodies and immunohistochemistry. Without you the first 
and second studies in this project would have been impossible.    
 58 
A big thank you goes to Wen Liu who guided me through study IV. I can only imagine the 
frustration of teaching me the basics of genetics, PCR and GWAS studies, but you managed 
to keep your cool and for that I am forever grateful.   
A person I will always remember and to whom I am most grateful is Berit Wejderot (R.I.P), 
who tragically passed away far too early. Berit was a key figure in management of the family 
trees of all families with Lynch Syndrome in Stockholm for many years, and knew many of 
the family members by name and home address. She dedicated her life to these families. 
Without her excellent administrative skills, the study III would not have been possible.  
I also have to thank my two “mothers” Anna-Lena Kastman and Nina Jäntti at the 
Genetics Lab at Bioclinicum during my work on the last study. Both of you took care of me 
since day one at the lab and made me feel welcome in the group. 
A warm thank you to senior consultant Sabine Naessén for your interest and help in my 
research project. 
A special thanks to my scientific comrades Igor Govorov and Zoia Razumova for your 
support. 
I want to thank all participants in the four studies for your great effort and patience with 
the study protocols, and for sharing your medical information to improve health for all 
women with HMB-E and EC. 
A special thanks goes to my dear friends and colleagues Addnan Jwayed and Jihan Hoseini 
at Vårbergs Vårdcentral, where I worked part time as a family doctor between 2017 and 
2019. You gave me the time to complete the necessary courses at KI and additional time for 
working with the last project of this thesis. I also had a wonderful time at the medical center, 
and it taught me so many valuable things about my strengths and weaknesses as a practicing 
doctor. I am forever grateful for your support.   
To my new clinical colleagues Ann-Sofie Backman, Markus Birk and Jan Björk at the 
department of gastroenterology, I just want to say that I am very happy to be a part of your 
team now, and I am so grateful that you have given me the chance to be a part of that team. I 
hope we can do joint research together in the future. 
A big thanks to all my medical internship (AT) colleagues with whom I worked at 
Huddinge Hospital between 2015 and 2017. Your own high ambitions and hard work ethic 
inspired me to continue on my own project during my internship. Our discussions about 
medicine and life have been invaluable in creating this book. 
 
 
 
  59 
A special thank you is to my beloved mother Sonia Andersson. Besides your greatest 
achievement as my mother, your other achievements that you have accomplished in life 
against all odds are always a constant source of inspiration for me in everything I do. You are 
the greatest example of the old saying that nothing is impossible if you have the ambition, 
and that has motivated me to carry on with this project. This thesis would not have been 
possible without you. You are the most amazing mother, friend and colleague in the world. 
An equally big thank you goes to my father Lennart Andersson. I thank my lucky stars 
every day that you do not have any knowledge at all about medical research, which has given 
me an opportunity to talk about other things when we sit around the dinner table with the 
family. You have always been supportive in everything I do, and your amazing kindness, 
humor and calmness have been essential for giving me the energy to write this thesis.  
I also want to thank my uncle Vladislav and my only cousin Michael for your fantastic 
support for me throughout life in general and during the making of this thesis in particular. 
Both of you are very intelligent people who always asks the toughest and most accurate 
questions when it comes to both private things in life and medical research aspects. Without 
that input this thesis would not have been possible.  
To my grandmother Violet Andersson and grandfather Ove Andersson I want to express my 
greatest respect. Even though we think differently about many issues in life, you have always 
supported my aspirations in the field of medicine. Ove in particular, who sadly passed away 
approximately two years ago, always had a great interest in medical research, and our 
discussions will be greatly missed. 
Also, a big thank you to my great aunt Aina Olausson, who has always been a great support 
to me since my childhood. I think that my interest in the field of biology actually arose while 
playing with your cats when I was a child. 
Two people that I cannot thank enough are my two best friends Daniel Meisels and Jakob 
Abramowicz. We have known each other almost a whole lifetime now, but our deep 
friendship has endured the test of time and evolved into a real brotherhood. I couldn’t have 
written this book without you. 
Last but not least I want to thank all my other relatives from near and far. Sadly, I never had 
the chance to know my maternal grandfather Isaac Tsesis and my maternal grandmother 
Milli Tsesis, but I think they would have been proud of what I and the rest of the family have 
accomplished thus far. This book wouldn’t have been possible without you two.  
  
 
 

  61 
8. REFERENCES 
1. Evans J, Salamonsen LA. Inflammation, leukocytes and menstruation. Rev 
Endocr Metab Disord. 2012;13(4):277-88. 
2. Garry R, Hart R, Karthigasu KA, Burke C. A re-appraisal of the morphological 
changes within the endometrium during menstruation: a hysteroscopic, histological and 
scanning electron microscopic study. Hum Reprod. 2009;24(6):1393-401. 
3. Critchley HO, Kelly RW, Baird DT, Brenner RM. Regulation of human 
endometrial function: mechanisms relevant to uterine bleeding. Reprod Biol Endocrinol. 
2006;4 Suppl 1:S5. 
4. Gargett CE, Rogers PA. Human endometrial angiogenesis. Reproduction. 
2001;121(2):181-6. 
5. Rogers PA. Structure and function of endometrial blood vessels. Hum Reprod 
Update. 1996;2(1):57-62. 
6. Chennazhi KP, Nayak NR. Regulation of angiogenesis in the primate 
endometrium: vascular endothelial growth factor. Semin Reprod Med. 2009;27(1):80-9. 
7. Nayak NR, Brenner RM. Vascular proliferation and vascular endothelial 
growth factor expression in the rhesus macaque endometrium. J Clin Endocrinol Metab. 
2002;87(4):1845-55. 
8. Kaitu'u-Lino TJ, Morison NB, Salamonsen LA. Estrogen is not essential for full 
endometrial restoration after breakdown: lessons from a mouse model. Endocrinology. 
2007;148(10):5105-11. 
9. Dosiou C, Giudice LC. Natural killer cells in pregnancy and recurrent 
pregnancy loss: endocrine and immunologic perspectives. Endocr Rev. 2005;26(1):44-62. 
10. Greenwood JD, Minhas K, di Santo JP, Makita M, Kiso Y, Croy BA. 
Ultrastructural studies of implantation sites from mice deficient in uterine natural killer cells. 
Placenta. 2000;21(7):693-702. 
11. Ashkar AA, Black GP, Wei Q, He H, Liang L, Head JR, et al. Assessment of 
requirements for IL-15 and IFN regulatory factors in uterine NK cell differentiation and 
function during pregnancy. J Immunol. 2003;171(6):2937-44. 
12. Girling JE, Rogers PA. Recent advances in endometrial angiogenesis research. 
Angiogenesis. 2005;8(2):89-99. 
13. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis. Cell. 1996;86(3):353-64. 
14. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. 
Endocr Rev. 1997;18(1):4-25. 
15. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, et al. 
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic 
cytokine. EXS. 1997;79:233-69. 
16. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol 
Aspects Med. 2008;29(5):290-308. 
17. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? 
Cell. 1996;87(7):1153-5. 
 62 
18. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671-4. 
19. Ono M, Shiina Y. Cytological evaluation of angiogenesis in endometrial 
aspirates. Cytopathology. 2001;12(1):37-43. 
20. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-
B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during 
embryonic blood vessel formation in the mouse. Development. 1999;126(14):3047-55. 
21. Smith SK. Regulation of angiogenesis in the endometrium. Trends Endocrinol 
Metab. 2001;12(4):147-51. 
22. Peters KG, De Vries C, Williams LT. Vascular endothelial growth factor 
receptor expression during embryogenesis and tissue repair suggests a role in endothelial 
differentiation and blood vessel growth. Proc Natl Acad Sci U S A. 1993;90(19):8915-9. 
23. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc 
Natl Acad Sci U S A. 1971;68(4):820-3. 
24. Kornberg A. Biologic synthesis of deoxyribonucleic acid. Science. 
1960;131(3412):1503-8. 
25. Li JJ, Kelly TJ. Simian virus 40 DNA replication in vitro. Proc Natl Acad Sci U 
S A. 1984;81(22):6973-7. 
26. Indiani C, O'Donnell M. The replication clamp-loading machine at work in the 
three domains of life. Nat Rev Mol Cell Biol. 2006;7(10):751-61. 
27. Martin A, Scharff MD. AID and mismatch repair in antibody diversification. 
Nat Rev Immunol. 2002;2(8):605-14. 
28. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic 
recombination, and cancer biology. Annu Rev Biochem. 1996;65:101-33. 
29. Weeks AD, Duffy SR, Walker JJ. A double-blind randomised trial of 
leuprorelin acetate prior to hysterectomy for dysfunctional uterine bleeding. BJOG. 
2000;107(3):323-8. 
30. Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, 
Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women 
with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004;190(5):1216-
23. 
31. Hapangama DK, Bulmer JN. Pathophysiology of heavy menstrual bleeding. 
Womens Health (Lond). 2016;12(1):3-13. 
32. Munro MG, Critchley HO, Broder MS, Fraser IS, Disorders FWGoM. FIGO 
classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid 
women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13. 
33. Karlsson TS, Marions LB, Edlund MG. Heavy menstrual bleeding significantly 
affects quality of life. Acta Obstet Gynecol Scand. 2014;93(1):52-7. 
34. Shaw ST, Jr., Aaronson DE, Moyer DL. Quantitation of menstrual blood loss--
further evaluation of the alkaline hematin method. Contraception. 1972;5(6):497-513. 
35. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using 
a pictorial chart. Br J Obstet Gynaecol. 1990;97(8):734-9. 
  63 
36. Davies J, Kadir RA. Heavy menstrual bleeding: An update on management. 
Thromb Res. 2017;151 Suppl 1:S70-S7. 
37. Bitzer J, Heikinheimo O, Nelson AL, Calaf-Alsina J, Fraser IS. Medical 
management of heavy menstrual bleeding: a comprehensive review of the literature. Obstet 
Gynecol Surv. 2015;70(2):115-30. 
38. Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. A 
Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine 
system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol 
Can. 2009;31(4):340-7. 
39. Shaaban MM, Zakherah MS, El-Nashar SA, Sayed GH. Levonorgestrel-
releasing intrauterine system compared to low dose combined oral contraceptive pills for 
idiopathic menorrhagia: a randomized clinical trial. Contraception. 2011;83(1):48-54. 
40. Cromwell DA, Mahmood TA, Templeton A, van der Meulen JH. Surgery for 
menorrhagia within English regions: variation in rates of endometrial ablation and 
hysterectomy. BJOG. 2009;116(10):1373-9. 
41. Cooper K, Lee A, Chien P, Raja E, Timmaraju V, Bhattacharya S. Outcomes 
following hysterectomy or endometrial ablation for heavy menstrual bleeding: retrospective 
analysis of hospital episode statistics in Scotland. BJOG. 2011;118(10):1171-9. 
42. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for 
heavy menstrual bleeding. Cochrane Database Syst Rev. 2003(2):CD003855. 
43. Roberts TE, Tsourapas A, Middleton LJ, Champaneria R, Daniels JP, Cooper 
KG, et al. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine 
system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ. 
2011;342:d2202. 
44. Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann 
J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, 
Treatment and Follow-up. Int J Gynecol Cancer. 2016;26(1):2-30. 
45. Lee NK, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS, et al. Prognostic 
factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;109(3):655-62. 
46. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-
917. 
47. Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. 
Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential 
diagnosis. Mod Pathol. 2006;19(8):1091-100. 
48. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. 
Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45(1):28-36. 
49. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast 
cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. 
Hum Reprod Update. 2014;20(5):748-58. 
50. Ring KL, Bruegl AS, Allen BA, Elkin EP, Singh N, Hartman AR, et al. 
Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer 
cohort. Mod Pathol. 2016;29(11):1381-9. 
 64 
51. Kooy J, Taylor NH, Healy DL, Rogers PA. Endothelial cell proliferation in the 
endometrium of women with menorrhagia and in women following endometrial ablation. 
Hum Reprod. 1996;11(5):1067-72. 
52. Mints M, Hultenby K, Zetterberg E, Blomgren B, Falconer C, Rogers R, et al. 
Wall discontinuities and increased expression of vascular endothelial growth factor-A and 
vascular endothelial growth factor receptors 1 and 2 in endometrial blood vessels of women 
with menorrhagia. Fertil Steril. 2007;88(3):691-7. 
53. Critchley HO, Maybin JA. Molecular and cellular causes of abnormal uterine 
bleeding of endometrial origin. Semin Reprod Med. 2011;29(5):400-9. 
54. Malik S, Day K, Perrault I, Charnock-Jones DS, Smith SK. Reduced levels of 
VEGF-A and MMP-2 and MMP-9 activity and increased TNF-alpha in menstrual 
endometrium and effluent in women with menorrhagia. Hum Reprod. 2006;21(8):2158-66. 
55. Hewett P, Nijjar S, Shams M, Morgan S, Gupta J, Ahmed A. Down-regulation 
of angiopoietin-1 expression in menorrhagia. Am J Pathol. 2002;160(3):773-80. 
56. O'Reilly G, Charnock-Jones DS, Davenport AP, Cameron IT, Smith SK. 
Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in 
human endometrium and a change in the ratio of ETA and ETB receptor subtype across the 
menstrual cycle. J Clin Endocrinol Metab. 1992;75(6):1545-9. 
57. Seki N, Kodama J, Hongo A, Miyagi Y, Yoshinouchi M, Kudo T. Vascular 
endothelial growth factor and platelet-derived endothelial cell growth factor expression are 
implicated in the angiogenesis of endometrial cancer. Eur J Cancer. 2000;36(1):68-73. 
58. Talvensaari-Mattila A, Soini Y, Santala M. VEGF and its receptors (flt-1 and 
KDR/flk-1) as prognostic indicators in endometrial carcinoma. Tumour Biol. 2005;26(2):81-
7. 
59. Yokoyama Y, Sato S, Futagami M, Fukushi Y, Sakamoto T, Umemoto M, et al. 
Prognostic significance of vascular endothelial growth factor and its receptors in endometrial 
carcinoma. Gynecol Oncol. 2000;77(3):413-8. 
60. Papa A, Zaccarelli E, Caruso D, Vici P, Benedetti Panici P, Tomao F. Targeting 
angiogenesis in endometrial cancer - new agents for tailored treatments. Expert Opin Investig 
Drugs. 2016;25(1):31-49. 
61. Mahecha AM, Wang H. The influence of vascular endothelial growth factor-A 
and matrix metalloproteinase-2 and -9 in angiogenesis, metastasis, and prognosis of 
endometrial cancer. Onco Targets Ther. 2017;10:4617-24. 
62. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances 
vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent 
signaling. FASEB J. 2002;16(8):771-80. 
63. Grybos A, Bar J. The relationships between the immunoexpression of KAI1, 
MMP-2, MMP-9 and steroid receptors expression in endometrial cancer. Folia Histochem 
Cytobiol. 2014;52(3):187-94. 
64. Honkavuori-Toivola M, Santala M, Soini Y, Turpeenniemi-Hujanen T, 
Talvensaari-Mattila A. Combination of strong MMP-2 and weak TIMP-2 immunostainings is 
a significant prognostic factor in endometrial carcinoma. Dis Markers. 2013;35(4):261-6. 
  65 
65. Yilmaz E, Koyuncuoglu M, Gorken IB, Okyay E, Saatli B, Ulukus EC, et al. 
Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid 
endometrial cancers and clinicopathologic significance. J Gynecol Oncol. 2011;22(2):89-96. 
66. Aglund K, Rauvala M, Puistola U, Angstrom T, Turpeenniemi-Hujanen T, 
Zackrisson B, et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-
9 correlates to the grade and the stage. Gynecol Oncol. 2004;94(3):699-704. 
67. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired 
recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks 
tumor angiogenesis and growth. Nat Med. 2001;7(11):1194-201. 
68. Yu L, Cecil J, Peng SB, Schrementi J, Kovacevic S, Paul D, et al. Identification 
and expression of novel isoforms of human stromal cell-derived factor 1. Gene. 
2006;374:174-9. 
69. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the 
hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow 
stromal cell niches. Immunity. 2006;25(6):977-88. 
70. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of 
neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. 
Blood. 2009;113(19):4711-9. 
71. Salcedo R, Oppenheim JJ. Role of chemokines in angiogenesis: CXCL12/SDF-
1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation. 
2003;10(3-4):359-70. 
72. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, et 
al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of 
CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived 
factor-1alpha. Am J Pathol. 1999;154(4):1125-35. 
73. Mirshahi F, Pourtau J, Li H, Muraine M, Trochon V, Legrand E, et al. SDF-1 
activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in 
vivo models. Thromb Res. 2000;99(6):587-94. 
74. Liu ZJ, Tian R, Li Y, Zhang L, Shao H, Yang C, et al. SDF-1alpha-induced 
dual pairs of E-selectin/ligand mediate endothelial progenitor cell homing to critical ischemia. 
Sci Rep. 2016;6:34416. 
75. Meng W, Xue S, Chen Y. The role of CXCL12 in tumor microenvironment. 
Gene. 2018;641:105-10. 
76. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. 
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to 
bone. Cancer Res. 2002;62(6):1832-7. 
77. Medina RJ, Barber CL, Sabatier F, Dignat-George F, Melero-Martin JM, 
Khosrotehrani K, et al. Endothelial Progenitors: A Consensus Statement on Nomenclature. 
Stem Cells Transl Med. 2017;6(5):1316-20. 
78. Bianconi V, Sahebkar A, Kovanen P, Bagaglia F, Ricciuti B, Calabro P, et al. 
Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm 
in cell therapy. Pharmacol Ther. 2018;181:156-68. 
 66 
79. Cheng M, Huang K, Zhou J, Yan D, Tang YL, Zhao TC, et al. A critical role of 
Src family kinase in SDF-1/CXCR4-mediated bone-marrow progenitor cell recruitment to the 
ischemic heart. J Mol Cell Cardiol. 2015;81:49-53. 
80. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH, et al. Plasma 
elevation of stromal cell-derived factor-1 induces mobilization of mature and immature 
hematopoietic progenitor and stem cells. Blood. 2001;97(11):3354-60. 
81. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman 
ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 
induction of SDF-1. Nat Med. 2004;10(8):858-64. 
82. Chavakis E, Koyanagi M, Dimmeler S. Enhancing the outcome of cell therapy 
for cardiac repair: progress from bench to bedside and back. Circulation. 2010;121(2):325-35. 
83. Matsubara Y, Matsubara K. Estrogen and progesterone play pivotal roles in 
endothelial progenitor cell proliferation. Reprod Biol Endocrinol. 2012;10:2. 
84. Zhuge Y, Regueiro MM, Tian R, Li Y, Xia X, Vazquez-Padron R, et al. The 
effect of estrogen on diabetic wound healing is mediated through increasing the function of 
various bone marrow-derived progenitor cells. J Vasc Surg. 2018;68(6S):127S-35S. 
85. Yu P, Zhang Z, Li S, Wen X, Quan W, Tian Q, et al. Progesterone modulates 
endothelial progenitor cell (EPC) viability through the CXCL12/CXCR4/PI3K/Akt signalling 
pathway. Cell Prolif. 2016;49(1):48-57. 
86. Yu P, Li S, Zhang Z, Wen X, Quan W, Tian Q, et al. Progesterone-mediated 
angiogenic activity of endothelial progenitor cell and angiogenesis in traumatic brain injury 
rats were antagonized by progesterone receptor antagonist. Cell Prolif. 2017;50(5). 
87. van Dijk CG, Nieuweboer FE, Pei JY, Xu YJ, Burgisser P, van Mulligen E, et 
al. The complex mural cell: pericyte function in health and disease. Int J Cardiol. 
2015;190:75-89. 
88. Allt G, Lawrenson JG. Pericytes: cell biology and pathology. Cells Tissues 
Organs. 2001;169(1):1-11. 
89. Shepro D, Morel NM. Pericyte physiology. FASEB J. 1993;7(11):1031-8. 
90. Sims DE. Diversity within pericytes. Clin Exp Pharmacol Physiol. 
2000;27(10):842-6. 
91. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of 
angiogenesis. Nature. 2011;473(7347):298-307. 
92. Stratman AN, Malotte KM, Mahan RD, Davis MJ, Davis GE. Pericyte 
recruitment during vasculogenic tube assembly stimulates endothelial basement membrane 
matrix formation. Blood. 2009;114(24):5091-101. 
93. Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health 
and disease. Nat Neurosci. 2011;14(11):1398-405. 
94. Hammes HP, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting 
vasoregression. Diabetes. 2011;60(1):9-16. 
95. Feng Y, vom Hagen F, Pfister F, Djokic S, Hoffmann S, Back W, et al. 
Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 
overexpression. Thromb Haemost. 2007;97(1):99-108. 
  67 
96. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and 
microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277(5323):242-5. 
97. Snieder H, MacGregor AJ, Spector TD. Genes control the cessation of a 
woman's reproductive life: a twin study of hysterectomy and age at menopause. J Clin 
Endocrinol Metab. 1998;83(6):1875-80. 
98. Kuzmina N, Palmblad J, Mints M. Predictive factors for the occurrence of 
idiopathic menorrhagia: evidence for a hereditary trait. Mol Med Rep. 2011;4(5):935-9. 
99. Awata T, Kurihara S, Takata N, Neda T, Iizuka H, Ohkubo T, et al. Functional 
VEGF C-634G polymorphism is associated with development of diabetic macular edema and 
correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun. 
2005;333(3):679-85. 
100. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of 
the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 
2003;63(4):812-6. 
101. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary 
factors in cancer. Study of two large midwestern kindreds. Arch Intern Med. 
1966;117(2):206-12. 
102. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. 
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): 
recommendations by a group of European experts. Gut.62(6):812-23. 
103. Silva FC, Valentin MD, Ferreira Fde O, Carraro DM, Rossi BM. Mismatch 
repair genes in Lynch syndrome: a review. Sao Paulo Med J. 2009;127(1):46-51. 
104. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for 
hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the 
International Collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453-6. 
105. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et 
al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch 
syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261-8. 
106. Wang Y, Wang Y, Li J, Cragun J, Hatch K, Chambers SK, et al. Lynch 
syndrome related endometrial cancer: clinical significance beyond the endometrium. J 
Hematol Oncol. 2013;6:22. 
107. Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B, Semotiuk K, et al. 
Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in 
mutation-positive patients with endometrial cancer encountered in the context of familial 
gastrointestinal cancer registries. Cancer. 2012;118(3):681-8. 
108. Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X, et al. 
Accuracy of revised Bethesda guidelines, microsatellite instability, and 
immunohistochemistry for the identification of patients with hereditary nonpolyposis 
colorectal cancer. JAMA. 2005;293(16):1986-94. 
109. Peltomaki P. Lynch syndrome genes. Fam Cancer. 2005;4(3):227-32. 
110. Folkins AK, Longacre TA. Hereditary gynaecological malignancies: advances 
in screening and treatment. Histopathology. 2013;62(1):2-30. 
111. Crispens MA. Endometrial and ovarian cancer in lynch syndrome. Clin Colon 
Rectal Surg.25(2):97-102. 
 68 
112. Wang Y, Li J, Cragun J, Hatch K, Chambers SK, Zheng W. Lynch syndrome 
related endometrial cancer: clinical significance beyond the endometrium. J Hematol 
Oncol.6:22. 
113. Gupta S, Provenzale D, Regenbogen SE, Hampel H, Slavin TP, Hall MJ, et al. 
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 
3.2017. J Natl Compr Canc Netw. 2017;15(12):1465-75. 
114. Johnatty SE, Tan YY, Buchanan DD, Bowman M, Walters RJ, Obermair A, et 
al. Family history of cancer predicts endometrial cancer risk independently of Lynch 
Syndrome: Implications for genetic counselling. Gynecol Oncol. 2017;147(2):381-7. 
115. Meyer LA, Westin SN, Lu KH, Milam MR. Genetic polymorphisms and 
endometrial cancer risk. Expert Rev Anticancer Ther. 2008;8(7):1159-67. 
116. Hirata H, Hinoda Y, Okayama N, Suehiro Y, Kawamoto K, Kikuno N, et al. 
CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer 
susceptibility. Cancer. 2008;112(9):1964-73. 
117. Tao MH, Cai Q, Zhang ZF, Xu WH, Kataoka N, Wen W, et al. Polymorphisms 
in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women. Cancer 
Epidemiol Biomarkers Prev. 2007;16(5):943-9. 
118. Paynter RA, Hankinson SE, Colditz GA, Kraft P, Hunter DJ, De Vivo I. 
CYP19 (aromatase) haplotypes and endometrial cancer risk. Int J Cancer. 2005;116(2):267-
74. 
119. Weiderpass E, Persson I, Melhus H, Wedren S, Kindmark A, Baron JA. 
Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis. 
2000;21(4):623-7. 
120. O'Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, et al. 
Identification of nine new susceptibility loci for endometrial cancer. Nat Commun. 
2018;9(1):3166. 
121. Cheng TH, Thompson DJ, O'Mara TA, Painter JN, Glubb DM, Flach S, et al. 
Five endometrial cancer risk loci identified through genome-wide association analysis. Nat 
Genet. 2016;48(6):667-74. 
122. Chen MM, O'Mara TA, Thompson DJ, Painter JN, Australian National 
Endometrial Cancer Study G, Attia J, et al. GWAS meta-analysis of 16 852 women identifies 
new susceptibility locus for endometrial cancer. Hum Mol Genet. 2016;25(12):2612-20. 
123. Liu N, Zhang K, Zhao H. Haplotype-association analysis. Adv Genet. 
2008;60:335-405. 
124. Sutton J, Orloff MS, Michener C, Chiesa-Vottero A, Prayson R, Nowacki AS, 
et al. Association of specific PTEN/10q haplotypes with endometrial cancer phenotypes in 
African-American and European American women. Gynecol Oncol. 2015;138(2):434-40. 
125. Hosono S, Matsuo K, Ito H, Oze I, Hirose K, Watanabe M, et al. 
Polymorphisms in base excision repair genes are associated with endometrial cancer risk 
among postmenopausal Japanese women. Int J Gynecol Cancer. 2013;23(9):1561-8. 
126. Carvajal-Carmona LG, O'Mara TA, Painter JN, Lose FA, Dennis J, 
Michailidou K, et al. Candidate locus analysis of the TERT-CLPTM1L cancer risk region on 
chromosome 5p15 identifies multiple independent variants associated with endometrial 
cancer risk. Hum Genet. 2015;134(2):231-45. 
  69 
127. Painter JN, O'Mara TA, Batra J, Cheng T, Lose FA, Dennis J, et al. Fine-
mapping of the HNF1B multicancer locus identifies candidate variants that mediate 
endometrial cancer risk. Hum Mol Genet. 2015;24(5):1478-92. 
128. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, 
et al. Risk of endometrial cancer following estrogen replacement with and without progestins. 
J Natl Cancer Inst. 1999;91(13):1131-7. 
129. Gabrielson M, Eriksson M, Hammarstrom M, Borgquist S, Leifland K, Czene 
K, et al. Cohort Profile: The Karolinska Mammography Project for Risk Prediction of Breast 
Cancer (KARMA). Int J Epidemiol. 2017;46(6):1740-1g. 
130. Brooks DL, Schwab LP, Krutilina R, Parke DN, Sethuraman A, Hoogewijs D, 
et al. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem 
cell activity and invasion in metastatic breast cancer models. Mol Cancer. 2016;15:26. 
131. Jin YP, Hu YP, Wu XS, Wu YS, Ye YY, Li HF, et al. miR-143-3p targeting of 
ITGA6 suppresses tumour growth and angiogenesis by downregulating PLGF expression via 
the PI3K/AKT pathway in gallbladder carcinoma. Cell Death Dis. 2018;9(2):182. 
132. Yasukochi Y, Sakuma J, Takeuchi I, Kato K, Oguri M, Fujimaki T, et al. 
Identification of three genetic variants as novel susceptibility loci for body mass index in a 
Japanese population. Physiol Genomics. 2018;50(3):179-89. 
133. Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, et al. miR-152 
is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial 
cancer. Cancer Res. 2011;71(20):6450-62. 
134. Ferlita A, Battaglia R, Andronico F, Caruso S, Cianci A, Purrello M, et al. Non-
Coding RNAs in Endometrial Physiopathology. Int J Mol Sci. 2018;19(7). 
135. Stender JD, Stossi F, Funk CC, Charn TH, Barnett DH, Katzenellenbogen BS. 
The estrogen-regulated transcription factor PITX1 coordinates gene-specific regulation by 
estrogen receptor-alpha in breast cancer cells. Mol Endocrinol. 2011;25(10):1699-709. 
136. Rafique S, Thomas JS, Sproul D, Bickmore WA. Estrogen-induced chromatin 
decondensation and nuclear re-organization linked to regional epigenetic regulation in breast 
cancer. Genome Biol. 2015;16:145. 
137. Elsheikh E, Sylven C, Ericzon BG, Palmblad J, Mints M. Cyclic variability of 
stromal cell-derived factor-1 and endothelial progenitor cells during the menstrual cycle. Int J 
Mol Med. 2011;27(2):221-6. 
138. Laird SM, Widdowson R, El-Sheikhi M, Hall AJ, Li TC. Expression of 
CXCL12 and CXCR4 in human endometrium; effects of CXCL12 on MMP production by 
human endometrial cells. Hum Reprod. 2011;26(5):1144-52. 
139. Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert RA, et 
al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood 
vessel formation. Circ Res. 2000;87(9):728-30. 
140. Foresta C, De Toni L, Di Mambro A, Ferlin A, Perilli L, Bertuzzi I, et al. Role 
of estrogen receptors in menstrual cycle-related neoangiogenesis and their influence on 
endothelial progenitor cell physiology. Fertil Steril. 2010;93(1):220-8. 
141. Foresta C, Zuccarello D, Biagioli A, De Toni L, Prana E, Nicoletti V, et al. 
Oestrogen stimulates endothelial progenitor cells via oestrogen receptor-alpha. Clin 
Endocrinol (Oxf). 2007;67(4):520-5. 
 70 
142. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et 
al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl 
J Med. 2003;348(7):593-600. 
143. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating 
endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353(10):999-
1007. 
144. Dong C, Goldschmidt-Clermont PJ. Endothelial progenitor cells: a promising 
therapeutic alternative for cardiovascular disease. J Interv Cardiol. 2007;20(2):93-9. 
145. Jujo K, Ii M, Losordo DW. Endothelial progenitor cells in neovascularization 
of infarcted myocardium. J Mol Cell Cardiol. 2008;45(4):530-44. 
146. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, et al. 
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 
2008;456(7223):809-13. 
147. Mints M, Blomgren B, Palmblad J. Expression of vascular endothelial growth 
factor receptor-3 in the endometrium in menorrhagia. Int J Mol Med. 2007;19(6):909-13. 
148. Mints M, Blomgren B, Palmblad J. Expression of angiopoietins 1, 2 and their 
common receptor tie-2 in relation to the size of endothelial lining gaps and expression of 
VEGF and VEGF receptors in idiopathic menorrhagia. Fertil Steril. 2010;94(2):701-7. 
149. Heryanto B, Lipson KE, Rogers PA. Effect of angiogenesis inhibitors on 
oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse. 
Reproduction. 2003;125(3):337-46. 
150. Girling JE, Lederman FL, Walter LM, Rogers PA. Progesterone, but not 
estrogen, stimulates vessel maturation in the mouse endometrium. Endocrinology. 
2007;148(11):5433-41. 
151. Abberton KM, Healy DL, Rogers PA. Smooth muscle alpha actin and myosin 
heavy chain expression in the vascular smooth muscle cells surrounding human endometrial 
arterioles. Hum Reprod. 1999;14(12):3095-100. 
152. Abberton KM, Taylor NH, Healy DL, Rogers PA. Vascular smooth muscle cell 
proliferation in arterioles of the human endometrium. Hum Reprod. 1999;14(4):1072-9. 
153. Abberton KM, Taylor NH, Healy DL, Rogers PA. Vascular smooth muscle 
alpha-actin distribution around endometrial arterioles during the menstrual cycle: increased 
expression during the perimenopause and lack of correlation with menorrhagia. Hum Reprod. 
1996;11(1):204-11. 
154. Tzortzatos G, Wersall O, Danielsson KG, Lindblom A, Tham E, Mints M. 
Familial cancer among consecutive uterine cancer patients in Sweden. Hered Cancer Clin 
Pract. 2014;12(1):14. 
155. de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A, Griffioen G, et 
al. Decrease in mortality in Lynch syndrome families because of surveillance. 
Gastroenterology. 2006;130(3):665-71. 
156. Renkonen-Sinisalo L, Butzow R, Leminen A, Lehtovirta P, Mecklin JP, 
Jarvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer 
syndrome. Int J Cancer. 2007;120(4):821-4. 
157. Dove-Edwin I, Boks D, Goff S, Kenter GG, Carpenter R, Vasen HF, et al. The 
outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of 
  71 
hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer. 
2002;94(6):1708-12. 
158. Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast, 
endometrial, and ovarian cancers. Steroids. 2015;99(Pt A):8-10. 
159. Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol. 2013;75:225-40. 
160. Felix AS, Yang HP, Bell DW, Sherman ME. Epidemiology of Endometrial 
Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences. Adv Exp Med Biol. 
2017;943:3-46. 
161. Savio AJ, Bapat B. Modulation of transcription factor binding and epigenetic 
regulation of the MLH1 CpG island and shore by polymorphism rs1800734 in colorectal 
cancer. Epigenetics. 2017;12(6):441-8. 
162. Kuroiwa-Trzmielina J, Wang F, Rapkins RW, Ward RL, Buchanan DD, Win 
AK, et al. SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus 
Associated with an Increased Risk of Developing MGMT-Methylated Colorectal Cancer. 
Clin Cancer Res. 2016;22(24):6266-77. 
163. Wang H, Lou D, Wang Z. Crosstalk of Genetic Variants, Allele-Specific DNA 
Methylation, and Environmental Factors for Complex Disease Risk. Front Genet. 
2018;9:695. 
164. Sha G, Zhang Y, Zhang C, Wan Y, Zhao Z, Li C, et al. Elevated levels of 
gremlin-1 in eutopic endometrium and peripheral serum in patients with endometriosis. Fertil 
Steril. 2009;91(2):350-8. 
165. Crispi S, Piccolo MT, D'Avino A, Donizetti A, Viceconte R, Spyrou M, et al. 
Transcriptional profiling of endometriosis tissues identifies genes related to organogenesis 
defects. J Cell Physiol. 2013;228(9):1927-34. 
166. Yang H, Gao Y, Feng T, Jin TB, Kang LL, Chen C. Meta-analysis of the 
rs4779584 polymorphism and colorectal cancer risk. PLoS One. 2014;9(2):e89736. 
167. Yang M, Zhai X, Ge T, Yang C, Lou G. miR-181a-5p Promotes Proliferation 
and Invasion and Inhibits Apoptosis of Cervical Cancer Cells via Regulating Inositol 
Polyphosphate-5-Phosphatase A (INPP5A). Oncol Res. 2018;26(5):703-12. 
168. Choi DS, Kim JH, Ryu HS, Kim HC, Han JH, Lee JS, et al. Syndecan-1, a key 
regulator of cell viability in endometrial cancer. Int J Cancer. 2007;121(4):741-50. 
169. Liu W, Jiao X, Thutkawkorapin J, Mahdessian H, Lindblom A. Cancer risk 
susceptibility loci in a Swedish population. Oncotarget. 2017;8(66):110300-10. 
170. Long B, Liu FW, Bristow RE. Disparities in uterine cancer epidemiology, 
treatment, and survival among African Americans in the United States. Gynecol Oncol. 
2013;130(3):652-9. 
171. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson 
BE. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J 
Epidemiol. 2007;165(3):262-70. 
172. Guttery DS, Blighe K, Polymeros K, Symonds RP, Macip S, Moss EL. Racial 
differences in endometrial cancer molecular portraits in The Cancer Genome Atlas. 
Oncotarget. 2018;9(24):17093-103. 
 
